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ABSTRACT  
 
Sunil K. Agarwal, MD, MPH: Association of Obstructive Airway Disease and Lung 
Function with Incident Heart Failure, and Optimal Prediction of Heart Failure in 
Community Settings: The Atherosclerosis Risk in Communities Study 
(Under the direction of Gerardo Heiss, MD, PhD) 
 
Background: This epidemiologic investigation of heart failure (HF) has two 
components, one focused on airway disease as a putative antecedent factor to 
HF and the other centered on the prediction of HF as a means toward reducing 
the growing burden of HF in the population.  
 
Methods Forced Expiratory volume-1 second (FEV1) and covariates were 
measured for the ARIC cohort in 1987-89. Incident HF was ascertained annually 
from hospital records and death certificates. Cox proportional hazards models 
were used to derive a risk score to predict 10 years risk of HF. Area under curve 
(AUC) and Net Reclassification Improvement (NRI) were estimated as measures 
of discrimination.  
 
Results Over an average follow-up of 14.9 years, 1369 (10%) ARIC participants 
free of HF at baseline had incident HF. The hazard ratios (HRs) for HF increased 
monotonically over descending quartiles of FEV1. The associations were seen in 
each of cigarette smoking strata, inclusive of never-smokers. After multivariable 
adjustment for traditional cardiovascular risk factors at baseline, the HRs of HF 
and their 95% confidence intervals (CI) comparing the lowest with the highest 
quartile of FEV1 were 3.91(2.40, 6.35) for white women, 3.03(2.12, 4.33) for 
white men, 2.11(1.33, 3.34) for black women and 2.23(1.37, 3.59) for black men. 
The multivariable adjusted hazards of HF were higher in those with FEV1/FVC < 
70% vs. ≥ 70%: HR 1.42 (95% CI 1.22, 1.68).  
 
The ARIC HF risk score included information easily available to the primary care 
physician including COPD. The estimated AUC of the ARIC HF risk score was 
0.810(optimism-corrected = 0.808), 95% CI = 0.807, 0.813. It was higher than 
AUC estimated using variables from the Framingham risk score(0.762) and the 
ABC risk score(0.784). Overall classification using the ARIC HF risk score 
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improved for 23.5% individuals relative to the Framingham, and 12.8% relative to 
the Health-ABC classification.  
 
Conclusions   In this population-based cohort, low FEV1, and obstructive 
respiratory illness were strongly and independently associated with incident HF. 
The underlying mechanisms may include diastolic-dysfunction, cor-pulmonale, 
silent-CHD, and require exploration. The ARIC HF risk score performs better 
than extant scores and may improve risk prediction of HF in the community. 
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 Chapter I 
SPECIFIC AIMS 
This doctoral research is set out with two primary goals. The first 
examined whether obstructive airway diseases are associated with higher 
incidence of heart failure in a middle aged cohort of black and white, men and 
women in four US communities. To this end, the presence of airway obstructive 
disease at baseline was ascertained using self reports and measured lung 
function, and classified according to Global Initiatives for Obstructive Lung 
Disease classification. In addition, the relationship between stature-adjusted 
continuous lung function measures, i.e., forced expiratory volume – 1 second 
(FEV1) and incident heart failure was examined. Further, the potential of 
inflammation as a mediator of the putative association was examined using an 
available set of systemic markers of inflammation. Finally, the sensitivity of the 
putative association to measurement error in the outcome was explored. 
 
The second goal developed a novel heart failure risk prediction function, 
the “ARIC heart failure risk score” and compared it with extant risk functions, and 
also examined the potential of novel biomarkers predictive of HF to improve the 
  2 
ARIC heart failure risk score.  The external validity of the extant heart 
failure risk scores, the Framingham Heart Study and Health ABC Study scores, 
were examined in a cohort of African American and white middle-aged men and 
women. Follow-up for new-onset hospitalization and mortality attributed to heart 
failure was available from 1996-98 through 2005. 
 
Novel estimation methods were used to evaluate the performance of the 
ARIC heart failure risk score relative to previously published methods.  
The specific aims are listed below:   
1a Test the association of lung function measures (FVC, and FEV1) with 
risk of incident heart failure (HF).  
i) Evaluate whether the above relationship differs by 
smoking status.  
ii) Evaluate  whether the above relationship is explained by 
coronary heart disease at baseline or during follow-up   
iii) Evaluate whether the above relationship is attenuated 
after adjusting for potential markers of inflammation/ 
hypercoagulability, and maximal inspiratory pressure (MIP), as these 
may be intermediary in the hypothesized associations.  
 
1b Test the association between baseline COPD (self report of 
productive cough, self report of physician diagnosis, and GOLD 
classification) with risk of incident HF.  
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2a Examine the validity of the extant HF risk scores in a population 
based cohort of middle aged black and white, men and women from four 
US communities.  
 
2b Derive a risk function with elements readily available to general 
practitioners to predict the 10 year risk of HF in a community based cohort 
of middle aged men and women. 
1) Compare its ability to discriminate between those who had HF from 
those who didn’t (discrimination) and concordance between expected 
and observed events by deciles of risk.  
2) Compare the performance of the ARIC HF risk score with the risk 
functions estimated in this study population using the variables from 
extant risk functions.  
3) Examine the performance of the ARIC HF risk score based on net 
reclassification improvement relative to the extant risk functions.   
 
2c Evaluate the incremental value of cystatin-C and hs-CRP for the 
prediction of HF. 
 Chapter II 
BACKGROUND AND SIGNIFICANCE 
2A. HEART FAILURE: Diagnosis, risk factors, predictors, and 
burden  
2.A.1 Public Health Burden of Heart Failure 
 
Heart Failure (HF) stands out as a major public health problem in the 
economically developed nations (Garg, Packer et al. 1993; Rosamond, Flegal et 
al. 2008). Its incidence approaches 10 per 1000 population after age 65 years 
(Lloyd-Jones, Larson et al. 2002), Despite improvements in medical 
management and advances in therapy, its incidence and prevalence have 
increased (Roger, Weston et al. 2004). Overall, it is estimated that about 5 million 
patients have HF in the U.S., and about 500,000 individuals are diagnosed with 
HF for the first time each year (Rosamond, Flegal et al. 2008). Its prognosis is 
grim (26% mortality at one year)(Levy, Kenchaiah et al. 2002) and the costs of its 
treatment exceed those for coronary artery disease and cancer combined (5.4% 
of the total US health care expenditures)(O'Connell and Bristow 1994).  
 
Nearly 300,000 patients are estimated to die of HF as a primary or 
contributory cause each year (Hunt, Abraham et al. 2005) – which probably 
represents a an underestimate of large magnitude(Anthony, Rosamond et al. 
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2009). Although age-adjusted mortality rates attributable to HF show a 
declining trend, the overall mortality has increased with the aging of the 
population (1998). The average one-year survival for individuals with ACC/AHA 
stage D HF is less than 20% (Ammar, Jacobsen et al. 2007), a prognosis worse 
than that of many common cancers (Hobbs 2002). The 2004 overall death rate 
per 100 for HF was 19.1, with the highest rate among black males (22.9) and the 
lowest in white females (18.3)(Rosamond, Flegal et al. 2007). Importantly, 
sudden cardiac death is common (40% of all deaths) among individuals with HF 
(Uretsky and Sheahan 1997).  
 
Healthcare burden and cost HF is the leading indication for hospitalization in the 
United States among patients older than 65 years. Hospital discharges with an 
HF diagnosis rose from 399,000 in 1979 to 1,009,000 in 2004 (Rosamond, Flegal 
et al. 2008). Of the estimated 22.6 million hospitalizations among >45 years old, 
HF was a diagnosis seen in about 19.2% of the hospital discharges. It was a  
primary discharge diagnosis in 4.7% (n=1.05 million) and secondary in  14.5% (n 
= 3.3 million) (unpublished; Agarwal, McNeill et al. 2009).   
 
Treatment costs for HF amount to 5.4% of the total health care 
expenditure (O'Connell and Bristow 1994). In 2001, $4.0 billion ($5912 per 
discharge) was paid to Medicare beneficiaries for CHF (Rosamond, Flegal et al. 
2007; Rosamond, Flegal et al. 2008). The estimated direct and indirect cost for 
HF in the United States was $33.2 billion in 2007 (Rosamond, Flegal et al. 2008).  
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2.A.2 The Challenge of Heart Failure Diagnosis in Primary Care Settings 
HF is a clinical syndrome and the result of complex pathological 
processes that culminate in the failure of the heart to circulate blood at normal 
pressure to meet the body’s need (Braunwald, Zipes et al. 2001). For diagnostic 
purposes the ACC/AHA advocate consideration of appropriate symptoms and 
signs when present, plus objective evidence and response to treatment when in 
doubt (Hunt, Abraham et al. 2005). Though sensitive, the signs and symptoms of 
HF have low specificity (Rutten, Cramer et al. 2006). This problem is accentuated 
due to their high prevalence in the elderly, the obese and in women (Dahlstrom 
2005). Importantly, unrecognized ventricular dysfunction and HF are frequent 
among individuals with comorbidities, many of whom have manifestations such 
as dyspnea and pedal edema (McDonagh, Morrison et al. 1997; Mosterd, Hoes 
et al. 1999).  There is ample evidence of misdiagnosis by physicians when 
objective criteria are used (Remes, Miettinen et al. 1991). Thus, a definitive 
diagnosis of HF entails the use of cardiac imaging (e.g. echocardiography and 
radio-nuclide ventriculography to assess left ventricular dysfunction), and referral 
to a cardiologist. 
 
Heart failure is broadly classified as systolic or diastolic in nature. At this 
point there is no standardized definition of diastolic dysfunction; it is mostly a 
diagnosis of exclusion of systolic heart failure (ejection fraction ≥50%) more 
commonly called as heart failure with preserved ejection fraction occurring within 
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72h of an HF event, i.e. the presence of symptoms of cardiac congestion and 
response to diuretics (Vasan and Levy 2000). However, recent studies have 
shown that as compared to systolic failure, diastolic failure is equally prevalent 
(Bursi, Weston et al. 2006), carries a similarly poor prognosis (Owan, Hodge et 
al. 2006), and requires treatment of comparable cost(Liao, Jollis et al. 2006). 
Population based studies have further reported that at least half of the individuals 
with systolic or diastolic left ventricular (LV) dysfunction on echocardiography 
have never been diagnosed as having heart failure (McDonagh, Morrison et al. 
1997; Mosterd, Hoes et al. 1999).  
 
To manage their patients well, primary care practitioners should be better 
able to recognize and quantify HF risk early by evaluating an individual’s risk of 
decompensation requiring hospitalization for HF. To this end, risk score functions 
may be helpful for timely referral and diagnosis in patients at high risk of HF.   
 
2.A.3. Major known risk factors 
Coronary Heart disease, Diabetes, Hypertension, Left ventricular 
hypertrophy, valvular heart disease are considered to be common and potentially 
modifiable risk factors of Heart Failure. Other common and increasing prevalent 
risk factors include higher body fat (reflected by high BMI or Waist 
Circumference), sleep apnea, and other traditional risk factors for CHD i.e., 
smoking, dyslipidemia are also distal risk factors for heart failure.  
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2.A.4 Predictors for incident heart failure in the community  
2.A.4.1 The role of history, symptoms, signs and ECG.  Considerable information 
is available to providers of primary care to assess and predict an individual’s risk 
of developing symptomatic HF, such as demographic information, medical 
history, physical examination, a basic biochemistry panel, and an ECG. The 
predictive accuracy of various co-morbid conditions, symptoms, signs and ECG 
patterns has been studied in both clinical and population settings, mostly in 
Caucasians. It has been reported that most of the symptoms and signs 
commonly associated with HF are sensitive but non-specific, while the less 
prevalent or subtle ones occurring in moderate to severe disease are specific, 
but less sensitive. A normal ECG is highly specific on the other hand, virtually 
ruling out HF or LV dysfunction (Rihal, Davis et al. 1995). Further, abnormal 
ECGs have been shown to have good sensitivity, i.e., 73-94% in a meta-analysis 
(Khunti, Squire et al. 2004) and 81% in the community-based EPICA study 
(Fonseca, Mota et al. 2004). Thus, a combined use of a patient’s history, physical 
exam, basic laboratory investigations and ECG may provide an optimum tool for 
patient risk stratification. This has been attempted to a limited extent on data 
from two cohorts, as discussed below. Studies using ARIC cohort data have 
found ECG parameters (Rautaharju, Prineas et al. 2007), renal function (Kottgen, 
Russell et al. 2007), diabetes (Pazin-Filho, Kottgen et al. 2008), and respiratory 
illness (Agarwal, Loehr et al. 2009) to be potential risk factors for incident HF.  
 
  9 
2.A.4.2 The potential role of biomarkers In recent years, biomarkers have been 
the focus of research in cardiovascular diseases to improve diagnosis. Despite 
their considerable potential and the low specificity of many other risk factors, 
biomarkers have not yet been considered for HF risk stratification.  
 
2.A.4.2a. High sensitivity C-reactive protein (hs-CRP) CRP is an acute phase 
protein produced by liver in response to increase in several pro-inflammatory 
cytokines, especially interleukin 6 and tumor necrosis factor. It is a well validated, 
systemic marker of inflammation. Several reports have suggested its 
independent association with incident HF(Kardys, Knetsch et al. 2006; Bahrami, 
Bluemke et al. 2008; Williams, Shah et al. 2008).  
 
2.A.4.2b. Cystatin C It is a cysteine protease inhibitor secreted by most human 
cells and metabolized in the proximal tubules in kidney after being freely filtered 
at the glomerulus. It is presently considered a more sensitive marker of mild renal 
dysfunction than creatinine and has been found associated with incident heart 
failure(Sarnak, Katz et al. 2005; Moran, Katz et al. 2008).  
 
2.A.4.2c N-terminal pro-B-type natriuretic peptide (NT-proBNP) Plasma B-type 
natriuretic peptide (BNP) and its amino terminal pro-hormone (NT-proBNP) are 
associated with sub-clinical cardiac structural and functional abnormalities, and 
with  incident HF in the general population (Wang, Larson et al. 2004; de Lemos 
and Hildebrandt 2008). NT-proBNP may thus enhance an efficient and simple 
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risk prediction of HF in the community (Ng, Geeranavar et al. 2004). Although the 
European Society of Cardiology has recently introduced BNP in the diagnostic 
algorithms of HF (Swedberg, Cleland et al. 2005), AHA awaits further 
investigations to clarify their role (Hunt, Abraham et al. 2005).  
 
2.A.4.2d. High Sensitivity Troponin T (hs-TropT).  Cardiac troponins in serum are 
highly specific markers of myocardial injury commonly used for the diagnosis of 
acute ischemic coronary events (Antman, Tanasijevic et al. 1996; Donnelly and 
Millar-Craig 1998; Lindahl, Toss et al. 2000; Apple, Wu et al. 2005).  Several 
studies have reported an association between increased concentrations of 
troponin measured in blood and HF prevalence, severity and prognosis (Sato, 
Yamada et al. 2001; Sato, Taniguchi et al. 2002; Setsuta, Seino et al. 2002; 
Horwich, Patel et al. 2003; Ishii, Cui et al. 2003; Del Carlo, Pereira-Barretto et al. 
2004), although concentrations are generally lower than those seen in patients 
with acute coronary syndromes (Aviles, Askari et al. 2002). The potential 
association of low levels of troponin T detected with highly sensitive assays with 
incident HF awaits investigation.  
 
B. COPD: definition, patho-physiology, and burden 
B.1 Definition. Chronic obstructive pulmonary disease (COPD) is characterized 
by non- or poorly reversible expiratory airflow limitation. The airflow limitation is 
usually progressive(Pauwels, Buist et al. 2001). Epidemiologic studies have for 
long used a questionnaire-based definition i.e., the presence of productive 
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sputum for at least 3 months during two consecutive years. There are two 
subtypes of COPD present in individuals to varying extent, i.e., chronic bronchitis 
and emphysema. Thus, varying degrees of pathological small airway obstruction 
and destruction of parenchyma constitute COPD.    
 
The American Thoracic Society (ATS) recommends the use lung function 
quantified by spirometry to define COPD. Forced vital capacity (FVC) refers to 
the maximum amount of air an individual can exhale after maximal inspiration. 
Forced expiratory volume in 1 second (FEV1) refers to maximum volume of air 
an individual can exhale in 1 second after maximal inspiration. A reduced ratio of 
FEV1 to FVC is an indicator of obstruction to air outflow during the early phase of 
exhalation. Figure 1 depicts the main volumes and capacities derived from 
spirometry readings.  
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Figure 1. Schematic depiction of Forced Expiratory volume in 1 second (FEV1) 
and Forced Vital Capacity.  
 
A lower peak flow is sensitive but not specific to diagnose COPD since it 
may be caused by other lung diseases as well as by poor effort.(Pauwels, Buist 
et al. 2001). Thus, there has been emphasis on the use of FEV1/FVC ratio for 
clinical purposes. A cut point of 0.7 for this ratio has been suggested to define 
presence of COPD, after verifying that this restriction is irreversible by using a 
bronchodilator. However, this ratio and its cut point may not be appropriate for all 
ages due to the age-related  decline of volumes, which affects FEV1 more than 
FVC. Thus, in this research we have focused on severe COPD which can be 
safely assumed to be age independent. The staging of COPD as suggested by 
the GOLD Executive Committee report is shown in Table 1.  
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B.2 Burden of Heart Failure. In contrast to the decrease in death rates from 
coronary heart disease and stroke the unadjusted death rates from COPD per 
100,000 residents of the US has increased from 2.1 in 1950 to 40.2 in 
2004.(NHLBI 2007) Further, these death rates are higher among whites (1/3rd for 
males and 2/3rd for females) than blacks. (NHLBI 2007) Among industrialized 
nations the rates were lowest for Japan in 2004, while US ranked among the 
nations with higher rates.  
 
B.3 Pathophysiology of COPD.  Although most patients with lung disease 
present chronic respiratory symptoms including productive cough before COPD, 
this is not always the case. The chronic airway disease components consist of 
mucus hypersecretion, ciliary dysfunction, airflow limitation. This, along with 
 
Table 1. Global Initiative for Chronic Lung Disease Classification for lung 
diseases 
Lung disease 
GOLD 
staging 
Definition 
No lung disease 
 No chronic respiratory symptoms & no 
lung function abnormality 
At risk of COPD 
0 Chronic respiratory symptoms & no 
lung function abnormality 
Restrictive 
 FEV1/FVC >= 0.70 and FVC < 80% 
predicted 
Mild COPD 
1 FEV1/FVC    <0.70 and FEV1>=80% 
predicted 
Moderate COPD 
2 FEV1/FVC    <0.70 and FEV1>=50 to < 
80% predicted 
Moderate/severe COPD 
3-4 FEV1/FVC    <0.70 and FEV1<50 
predicted 
GOLD: Global Initiative on Lung Disease classification 
The ARIC study didn’t evaluate response to bronchodilator hence the levels are 
based on “pre-bronchodilator’’ functions. Also total lung volume was not 
available, thus it was difficult to define strict category of restrictive disease.  
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alveoli destruction leads to subsequent pulmonary hyperinflation, gas exchange 
abnormalities, pulmonary hypertension, and cor-pulmonale (Pauwels, Buist et al. 
2001).  
 
There is a gradual decline with pulmonary function (volumes) with age 
accompanied by mild inflammation called senile emphysema.  In a recent review, 
Iko et al. suggested that COPD represents a state of accelerated decline in lung 
function mediated by increased systemic and local inflammation (Tkac, Man et al. 
2007). Smoking, air pollution, and exposure to noxious air stimuli are known, 
strong risk factors for the development of COPD. Other risk factors such as 
absence of alpha-1 anti-trypsin enzyme are uncommon.  
C. COPD/Lung function and Heart Failure 
HF is common among patients with chronic obstructive pulmonary disease 
(COPD) and vice versa (Dahlstrom 2005; Rutten, Cramer et al. 2006). As seen in 
Table 2, in a nationally representative sample of about 20% of all hospitalizations 
in community hospitals across the US, a concomitant ICD code of COPD was 
present in 34.6% of the hospitalizations with an ICD code for HF (Agarwal, 
McNeill et al., unpublished).  
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Table 2. Common comorbidities seen in hospital discharges among ≥ 45 years 
from the community hospitals in the United States: The National Inpatient 
Sample 2006 (Agarwal, McNeill et al. 2009) 
 HF code in the discharge diagnosis 
Condition Definition 
Primary 
position 
Secondary 
position 
Absent 
 
Coronary atherosclerosis  0.54 0.46 0.25 
Cardiac dysrhythmia 0.44 0.41 0.16 
Essential hypertension 0.43 0.40 0.49 
Chronic obstructive pulmonary 
disease 0.31 0.33 0.15 
Diabetes mellitus without 
complication 0.30 0.25 0.19 
Disorders of lipid metabolism 0.27 0.23 0.26 
Heart valve disorders 0.27 0.18 0.06 
Hypertension with complications and 
2* HTN 0.23 0.24 0.08 
Deficiency and other anemia 0.22 0.23 0.16 
Fluid and electrolyte disorders 0.22 0.32 0.21 
Peri/endo/myocarditis or 
cardiomyopathy 0.21 0.12 0.02 
Chronic renal failure 0.20 0.18 0.06 
Conduction disorders 0.20 0.13 0.05 
 
COPD complicates both the diagnosis and treatment of HF. Both COPD 
and HF may present with symptoms of dyspnea and orthopnea. If beta blockers 
are indicated in a patient with HF, the presence of COPD, necessitates the use of 
low-dose cardio-selective beta blockers with slow titration(Cazzola and Matera 
2008).  
Several lines of research point to a common soil for COPD and HF.  A 
vast literature suggests a higher cardiovascular mortality in individuals with 
COPD and reduced lung function. Factors such as chronic muscle wasting, 
autonomic dysfunction, systemic inflammation(Schroeder, Welch et al. 2003), or 
oxidative stress(Mannino, Doherty et al. 2006) may be responsible for this 
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increased risk.  In the context of diseases affecting structure and function of lung 
pulmonary hypertension and cardiac dysfunction i.e. cor-pulmonale is well 
known(Budev, Arroliga et al. 2003). In addition, influenza vaccination, primarily 
reducing serious lung disease and mortality(Nichol, Margolis et al. 1994), also 
prevents new onset of HF(Davis, Taubert et al. 2006). A schematic 
representation of several pathways leading to Heart Failure is shown in figure 2.  
 
 
 
Chronic obstructive Pulmonary 
disease Incident Heart Failure
Smoking
Air Pollution
Age
Gender
Race
CHD=coronary heart disease; obesity measured as BMI; WC; WHR. 
Obesity 
Occupation
Education
Pulmonary 
Hypertension
Genes
?
Inflammation
CHD
Diabetes 
Hypertension
 
 
Figure 2. Conceptual framework of factors linking COPD and heart failure. This is 
not a Directed Acyclic Graph as several constructs may effect each other at the 
same time as well as temporally thus have potential to act as both confounder as 
well as intermediary.  
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D. Studies of COPD /Lung function) as a Risk Factor for Heart 
Failure 
In a longitudinal study published in 1974, Kannel et al. examined the 
relationship between forced vital capacity and incident heart failure in the 
Framingham Heart Study. The authors reported that both a persistently low and a 
recent fall in vital capacity were associated with increased risk of HF. However, 
they did not find an association between obstructive disease (FEV1/FVC) and 
incident HF. In a case control study published in 2005, Sidney et al. have 
reported an association between COPD associated with incident HF, RR = 3.75 
(95% CI: 3.39, 4.15) using a large administrative dataset (Kaiser Permanente 
Medical Care Program).  
E. Validation of ICD code ‘428.x’ for the diagnosis of HF 
In her thesis, available electronically (UMI: 3322231), Dr. Laura R. Loehr 
summarizes five studies examining the validity of ICD codes for defining heart 
failure(Loehr 2008). There was considerable variability in the estimates from  
these studies, and the lack of a uniform gold standard is a contributor to this. The 
ARIC study heart failure surveillance results provide a better framework to 
understand this issue since HF status is ascertained using several standardized 
classification criteria and a meticulous review by a panel of physicians. In a 
sample of hospitalizations with suspected CHD, the PPV of HF diagnosis was 
83.5% while sensitivity was 62.8%, when using a physician diagnosis or 
pulmonary edema on X-ray as gold standard [136. A hospital discharge 
diagnosis of ICD  9-DM- 428.x was reported to have a positive predictive value of 
94.3% when compared to the Framingham criteria (Lee, Donovan et al. 2005).  
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In the ARIC HF surveillance study based on a sample of hospitalizations 
with high suspicion of HF, the PPV of an ICD code ‘428.x’ for HF classified 
according to ARIC study procedures was 77%, and its sensitivity was 95% 
(Rosamond, Chang et al. 2009).  In the same study the corresponding PPV and 
sensitivity of an ICD code ‘428.x’ for HF defined by the Framingham Heart 
Failure criteria was 0.78, and 0.83, respectively.  
 
F. Risk score functions and their utility  
2.F.1 Early diagnosis improves outcomes. While there has been progress in the 
therapy of HF leading to better survival during the last decades, many 
researchers agree that future efforts need to be directed towards early detection 
of ventricular dysfunction and prevention of symptomatic heart failure(Fonseca 
2006). Highlighting the importance of early diagnosis and treatment in individuals 
with LV systolic dysfunction, the Study of Left Ventricular Dysfunction (SOLVD) 
trial showed that patients randomized to enalapril (an ACE inhibitor) had lower 
late mortality and lower serious CV morbidity as compared to placebo who also 
received enalapril at the trial close out (Ahn, Jong et al. 2006). This becomes 
particularly important in light of the high proportion of sudden cardiac death 
among individuals with mild HF (Uretsky and Sheahan 1997). Thus, an early and 
accurate HF diagnosis can be viewed as the cornerstone of improved patient 
outcome.  
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2.F.2 Early diagnosis/referral in primary care setting improves outcomes.  Most 
patients with HF present for the first time to general practitioners (GPs) and are 
mostly managed by them (Fowler 1997). Results of a qualitative study involving 
focus groups of 30 GPs in four primary care settings in the UK showed that lack 
of confidence in establishing diagnosis, rapidly changing knowledge and doubts 
about the applicability of research to primary care settings were identified as 
main barriers to providing standard care to patients with HF in the community 
(Fuat, Hungin et al. 2003). Whereas accurate diagnosis is crucial for effective 
management, many practitioners at the primary care level rely on clinical 
elements to diagnose heart failure without further investigation, thus deviating 
from the available guidelines (Fonseca 2006). Furthermore, the importance of 
early diagnosis and treatment of left ventricular systolic dysfunction was not fully 
appreciated among general practitioners (Mair and Bundred 1996). A review of 
HF patients’ charts in Netherlands reported that although general practitioners 
had more elderly and female patients, they asked for fewer tests and also 
prescribed potentially beneficial medications less often compared to cardiologists 
(Rutten, Grobbee et al. 2003).  Similarly, a large multinational European survey 
of patients with HF reported that while 92% of the treating physicians asked for 
an electrocardiogram (ECG), only 45% asked for an echocardiogram (Cleland, 
Cohen-Solal et al. 2002). Thus, primary care practitioners, though providing most 
of the care for HF, confront difficulties in the recognition and diagnosis of HF.   
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2.F.3 Risk score functions as an aid to stratification and referral.  Clinical 
prediction models combine patient characteristics to predict the probability that a 
particular disease state will occur. Risk scores based on an optimal set of 
predictors demonstrably predict the probability of incident cardiovascular events 
in various populations (D'Agostino, Grundy et al. 2001). Their use for the risk 
management of CHD has been strongly encouraged in the NCEP- ATP III 
guidelines (2001), and made available by NHLBI for use in clinical practice . Risk 
score functions may be particularly useful in the identification of groups at 
intermediate risk  and they are now recognized as essential in efficiently 
identifying likely candidates for CHD (Kannel, D'Agostino et al. 2004).  
 
Unlike most manifestations of CHD, ventricular dysfunction remains 
masked and undetected in majority of its carriers, though early identification and 
proactive management could improve health outcomes. Further, comorbidities – 
particularly those affecting the lungs (Kannel, Seidman et al. 1974) or kidneys 
(Kottgen, Russell et al. 2007) – may contribute to or precipitate cardiac 
decompensation in the absence of manifest CHD.  Particularly in this context, 
various biomarkers may be of value as elements of risk score functions.  
 
2.F.4 Strengths and limitations of the existing risk functions. The HF risk score 
function derived by the Framingham Heart Study (FHS) investigators and a 
recently published risk score from the Health, Aging, and Body Composition 
(Health ABC) study are the only published tools available for predicting incident 
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HF. Their main features are summarized in Table 3. The FHS is restricted to 
white examinees and provides a full score that includes elements with limited 
availability to primary care practitioners such as forced vital capacity and X-Ray. 
 
 
Table 3. Comparison of study design and elements for the existing and proposed HF risk 
score 
 FHS complete   Health ABC score ARIC Study  
Study 
characteristics    
Sampling  Community based 
selected: relatively 
healthy community based 
Age at baseline 
(range) 45-94y 70-79y 52-75y 
Sample size 
5209(?, not 
mentioned) 2935 10781 
Follow up HF events 486 258 1000+ 
Risk predicted for 
years 4 5 4, 5 and 10 
% Black 0 40 23 
Outcome 
ascertainment using 
Framingham 
criteria  
Adjudicated ICD 
codes 
Adjudicated ICD 
codes 
Methods used 
Pooled logistic 
regression Cox regression 
Cox reg. and newer 
methods 
Subset analysis None 
Group with CHD, 
HTN, VHD Race, and gender 
Internal validation None Bootstrapping  Bootstrapping  
External validation 
tested for  FHS abbreviated 
FHS and Health 
ABC study 
External validation 
study  
Health ABC 
cohort None -------- 
Data elements used    
Age X X X 
Left ventricular 
hypertrophy X X X 
Vital capacity X  X 
Heart rate X X X 
Systolic blood 
pressure X X X 
Coronary heart 
disease X X X 
Valvular   disease 
(auscultation) X  X 
Diabetes X 
Fasting blood 
glucose X 
Cardiomegaly  
(X-Ray) X   
Smoking status  X X 
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Albumin  X X 
Creatinine  X X 
Cystatin C   X 
Prolonged  
QRS interval   X  
C reactive protein   X  
 
Although the Health ABC study has validated the former score in a 
population of older adults, an external validation of the Framingham HF risk 
score in a similar population is pending since external validation in an 
independent test data set is an accepted requisite before the use of such models 
can be recommended (Ripley 1996). The Health ABC cohort includes older black 
and white participants, but no information on calibration or discrimination of the 
score for blacks was provided. The Health ABC study tested some variables not 
included by FHS, i.e. smoking, serum albumin and creatinine. Both studies 
included left ventricular hypertrophy, which is uncommon in middle aged 
participants and not easily accessible to primary care physicians. It is also 
relevant to note that conditions of high prevalence such as other ECG 
abnormalities, respiratory illness, and obesity deserve to be tested for their 
potential ability to modify the basic risk function estimated from these data. 
Hence, an external validation of both the risk scores and an assessment of the 
relative importance of the variables used in their calculation represent timely and 
informative contributions. For reasons mentioned above, an HF risk score that 
performs well in the primary care setting would have wide applicability and 
potential impact. It’s noteworthy that each of the above studies had a limited 
number of events, thus restricting the statistical power available to test the 
incremental value of putatively important predictors. Further, better methods are 
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being investigated for prediction with censored data (Chambless and Diao 2006), 
and reclassification is relied on at present to assess the performance of risk 
functions more so than on traditional approaches based on an increase in the 
area under the ROC curve (Pencina, D' Agostino RB et al. 2008; Pepe, Feng et 
al. 2008). As evidenced by risk predictions for incident CHD, prognostic 
statements for 5 to 10 years are of value in the prevention and management of 
chronic disease. Of note, the Framingham and Health ABC studies did not 
provide information on long term risk prediction beyond 4-5 years. Lastly, the 
additional use of novel biomarkers in these equations or their calibrated versions 
will be a timely and potentially important innovation by this study.  
  
G. Methods to Adjust for Bias 
The primary concerns with bias in this project apply to misclassification of 
hospitalized HF and their potential contamination with COPD exacerbations 
given the many overlapping signs and symptoms(Hawkins, Petrie et al. 2009), 
and  optimism in the estimation of primary discrimination statistics of the HF risk 
functions estimated in the ARIC cohort since the derivation and testing samples 
are the same.  
 
The first concern regarding outcome misclassification in an exposure-
outcome study was partly resolved by sensitivity analysis.  To evaluate whether 
our findings may be a result of misclassification of incident HF, sensitivity 
analyses were conducted as follows: a) analyses excluding participants with self 
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reported COPD; b) replicate analyses excluding participants with prevalent CHD; 
c) excluding both baseline COPD and prevalent CHD; and d) , analyses that 
excluded those with acute exacerbation of COPD during HF hospitalization (n=  
78), those with acute exacerbation of COPD or respiratory failure (n=229) during 
a hospitalization coded as HF, and e) censoring those with acute exacerbation of 
COPD or  respiratory failure (n=229) during HF hospitalization. The second 
concern, namely optimism in the estimation of the AUC was addressed by 
subtracting an estimate of optimism derived by using 1000 bootstrap samples 
from the AUC estimate.  
 
H. Summary and public health significance 
Heart Failure is a common condition in economically developed countries 
and at the root of a large and growing burden of disability, early death, and health 
care expenditures. Despite large allocations of resources to its medical care, its 
prognosis remains grim. Identification of novel risk factors and pathways for HF 
may prevent or delay decompensated, hospitalized HF and also motivate the 
development of new therapeutic targets. While the rate of mortality attributable to 
heart disease is declining, COPD remains a primary public health concern as 
well as the only condition with an increasing of mortality in the U.S. This study 
tests association between reduced lung function and incident HF after 
adjustment for potential confounders in a large community based cohort. It also 
explores whether markers of inflammation may be partially explain or be 
mediator of this association.  
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HF is mostly managed in primary care settings. It is a clinical syndrome, 
diagnosed with the aid of a combination of signs, symptoms and laboratory and 
imaging studies. Owing to the low specificity of individual signs and symptoms it 
is challenging to diagnose HF early and accurately in community settings.  
Importantly, early diagnosis and management are beneficial in delaying the 
occurrence of decompensated HF and of poor outcomes in patients with HF. An 
accurate risk prediction function may provide important information about an 
individual’s risk of future events. This is particularly important for HF patients as 
mild, asymptomatic left ventricular dysfunction (systolic as well as diastolic) is 
common in the community, and a large proportion of individuals with HF suffer 
sudden cardiac death, even with mildly symptomatic HF.  This study evaluates 
the external validity of the two existing HF risk scores in a large bi-racial cohort of 
middle-aged men and women in four US communities. Further, this study 
examines the potential value of few biomarkers in enhancing HF risk prediction 
functions. Identification of individuals at risk of developing HF can contribute to 
scheduling of care visits, early referral, proactive management, and improved 
health outcomes.  
 
 Chapter III 
METHODS  
A. Study population  
The source population that comprises the ARIC study was a community 
based sample of males and females, ages 45-64 at enrollment, from 4 US 
communities. The race/ethnic composition reflects that of two communities 
(seven suburbs of Minneapolis, MN and Washington County, MD) whereas 
African Americans were over sampled in Forsyth County, NC and Jackson MS 
participants were restricted to age-eligible African Americans. The over-sampling 
of African American participants (approximately 27% of the participants at 
baseline exam) was a deliberate effort to investigate minority health related 
issues. At baseline, approximately 50% of the participants were female. As the 
ARIC study was designed to assess sub-clinical cardiovascular disease in a 
middle aged –population, it was not felt that inclusion of persons under age 45 
would contribute to study objectives, thus enrollment was restricted to persons 45 
years and older. Racial groups not classified as white or black will be excluded in 
this study due to their limited numbers at study baseline (n=48 ).   
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Table 4. ARIC study population by race at study enrollment 
 Black, not of Hispanic origin White, not of Hispanic origin Total 
Female 2635 6050 8710 
Male 1631 5428 7082 
Total 4266 11478 15792 
 
 
B. Protection of Human Subjects 
This project used extant ARIC data, and measures covered by the 
informed consent provided by each study participant.  Neither the measures used 
in these analyses nor the resulting estimates of HF risk are reportable to the 
cohort members or their providers of medical care.  The ARIC study adheres to a 
well established and standardized data collection protocol, which is reviewed and 
annually approved by institutional review boards at each participating institution. 
IRB approval to support this proposed analysis was obtained in September 2008. 
The ARIC study investigators have approved the release a de-identified data file 
containing requested variables to the investigator.  The investigator has signed a 
data use agreement indicating that the clinical data, biological materials, modified 
or unmodified derivatives thereof, will not be used contrary to specifications 
stated in the study subjects’  informed consent. Further, both the studies of this 
project were approved by the Institutional Review Board of the University of 
North Carolina at Chapel Hill.  
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C. Ascertainment of heart failure events  
The ARIC Study enrolled 15,792 subjects aged 45-64 years in four U.S. 
communities: Forsyth County, NC; Jackson, MS; seven northwestern suburbs of 
Minneapolis, MN; and Washington County, MD.  Enrollment at the Jackson, MS 
site was restricted to black residents, while black residents were over-sampled in 
Forsyth County. Baseline examinations of the cohort were conducted from 1987 
to 1989 to collect information about socioeconomic indicators, medical history, 
family history, cardiovascular risk factors, serum chemistries, ECGs, medication 
use, and lung volumes.  The cohort participated in four examinations including 
baseline visit, annual telephone interviews and active surveillance of their 
hospitalizations and death.  
 
D. Incident heart failure event criteria  
Incident HF was defined as the first HF hospitalization with an HF 
discharge code or HF as the underlying cause of death on a death certificate 
(n=84). Hospital discharge diagnoses were coded using the International 
Classification of Diseases Code, Ninth Revision (ICD-9, code 428), and deaths 
were coded using ICD-9 or ICD-10 (codes 428 and I 50, respectively).  Cohort 
follow up for the current analysis ended on 31st December 2005. 
 
  29 
E. Measurement of primary exposures:  
Lung functions 
At the baseline visit, pulmonary function was assessed using a water-
sealed Collin Survey II volume displacement spirometer. Spirometry was 
conducted using American Thoracic Society guidelines(1987). From at least 
three acceptable readings, of which at least two were reproducible (volumes 
within ± 5%), a best reading was selected by computer and confirmed by 
technician. Methodology was standardized across four field centers including 
training and certification of pulmonary technicians.  
COPD  
History of respiratory illness was obtained from standardized 
questionnaire(Ferris 1978) by trained personnel. 
F. Baseline covariate definitions  
At baseline, prevalent coronary heart disease (CHD) was ascertained by 
self-report and a 12-lead ECG. Hypertension was defined by diastolic pressure≥ 
90 mm Hg or systolic pressure≥140 mm Hg on the average of the last 2 of 3 
measurements, or the use of anti-hypertensive medications. Diabetes was 
defined by the presence of serum glucose level >= 200 mg/dl, an 8-hour fasting 
glucose level >=126 mg/dl, a self-reported history of physician-diagnosed 
diabetes, or the current use of hypo/antihyper-glycemic medications. Other 
medications intake including beta blockers was self-reported or derived from 
  30 
medicines brought by participants during exam. Cigarette smoking status was 
defined as currently smoking or a history of ever smoking four hundred cigarettes 
or more. The average number of cigarettes/day and number of years of smoking 
reported were multiplied to derive cigarette-years of smoking. Body mass index 
was defined as the ratio of measured weight (kilograms) and measured height2 
(in meters2). Participants identified themselves as belonging to 
American/Alaskan Indian, Asian, black, or white race. 
G. Statistical power analysis  
G1. Cox Regression Power analysis  was done using a total sample at risk visit 4 
= 10781, follow up period = 5 years and 10 years, alpha = 0.05 (two-sided), 
exposure proportion at baseline = 10% and 40% and median time to event 
among unexposed = 4.5 and 9 years (conservative).  
There is 80% power to detect a hazard of 1.13 when using 5 years follow 
up and 10% prevalence (conservative for some risk factors like hypertension).  
Similar, analysis was done by restricting the sample size at baseline to that of 
African American (n=2425), other parameters being same. For 5 years follow up 
and a variable with 10% prevalence there is 80% power to detect an alternative  
HR>1.3.  Also, the number of variables fitted in the multivariable model * 10 is 
less than number of HF(Rothman 2002), hence degrees of freedom available for 
calculation of coefficients should not be a problem.  
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Figure 3. Minimum hazard ratio detectable with study size under range of power.  
 
Hence, there seems to be enough power to identify important predictors 
using Cox regression. The above power analysis was done using PS software 
(Schoenfeld and Richter 1982).  
 
 
G2. Minimum detectable differences in area under curve on a two sided null 
hypothesis at alpha = 0.05 and beta = 0.2 and 0.1 is shown in table 5.  The two 
study samples shown are for the overall cohort and for African American sub-
sample. The estimates make the assumption of a correlation of 0.6 for both false 
positive and false negative on two risk functions, which is conservative as we 
expect high correlation. Further, we wish to test one sided hypothesis of whether 
inclusion of variable improves the AUC, hence these estimates are even more 
conservative. Also, the two issues of partial AUC, and risk-cut off for decision 
Graph showing alternative hazard when 10 % of all or African Americans in the study are exposed and 
followed up for 5 years 
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making dictate power. Novel methods of reclassification outlined above will 
provide more power. We will use cut-offs similar to those for coronary artery 
disease.  
 
 
 
Statistical Analysis 
SAS, version-9.1 and STATA-IC, version-10 software were used for 
analysis. A p<0.05 for a two-sided test was considered statistically significant. 
Means (standard deviations) and proportions of characteristics at baseline and 
follow up HF event rates were calculated for quartiles of FEV1. A higher 
proportion of blacks and women were in the lower quartiles of FEV1 and FVC; 
thus all analysis (except for table 7) used race and gender specific quartiles of 
FEV1. 
General consideration of time to event analysis:  
A participant susceptible to event of interest is said to be at-risk for the 
event. In this study, those with prevalent HF were not susceptible to an incident 
event and thus were removed from the analysis.  The duration when someone is 
 
Table 5. Area under receptor operating curve: minimum difference in AUC 
detectable at two values of power 
HF No HF AUC under null 
Min Diff at 
power = 0.8 
1000 9781 0.5 0.023 
1000 9781 0.6 0.024 
1000 9781 0.7 0.024 
1000 9781 0.8 0.025 
270 2165 0.5 0.042 
270 2165 0.6 0.043 
270 2165 0.7 0.044 
270 2165 0.8 0.045 
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not susceptible for the event such as person-time before origin, after a non-
repeating event of interest such as incident heart failure, and after a competing 
event such as death and still contributes to person time is said to be contributing 
to immortal time. The origin in this study was enrollment in the study and then 
participants were followed every year with an annual follow up interview and 
surveillance of community hospitals. If a participant enters study prior to 
becoming at-risk, then the time from study entry to onset of risk is not time at-
risk, but is called immortal person-time. Hence, there is no evident immortal 
person time in the study. Most of the individuals censored in the study were due 
to administrative censoring or due to death. We can assume with some 
confidence that most of censoring (due to administrative censoring) is non-
informative censoring, or independent censoring.  
 
Poisson regression  
A Poisson regression model allows us to quantify the incidence density (# 
of events/person time at risk) as a function of many exposures and covariates.  
 
The Poisson regression model can be represented as  
 
( )k exp Xλ = α +β + γZ or klog Xλ = α +β + γZ  
where index k = 1, 2, …, K levels of the joint exposure X and covariate vector Z.. 
The intercept coefficient α (with log y accounted for) is the incidence density for 
the group defined by a value of zero on the exposure and covariate vector. The 
coefficient vector γ are the log incidence density ratios for unit changes in the 
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respective components of covariate vector Z, holding exposure (and other 
components of Z) constant at any level. Incidence density (rate) of HF in various 
strata was estimated assuming a Poisson distribution.  
 
Hazards and Cox regression model 
Hazard is defined as instantaneous risk at a given time. It can be 
represented as probability of event in a small interval. Usually it is estimated at 
each event. ( ) ( )
t 0
h t lim Pr t T t t | W t T t
∆ →
= < ≤ + ∆ < ≤ ∆ .  
The Cox proportional hazards model can be represented as 
 ( ) ( ) ( )0h t h t exp X= × β + γZ ,  
where h0(t) is the reference hazard function for those with X = Z = 0 and is 
sometimes called the baseline hazard function. Cox proportional hazards model 
is semi-parametric and doesn’t has an intercept coefficient. In this model β 
coefficient is the log of hazard ratio per unit change in exposure X while holding 
other variables constant at any level and γ is the vectors of log hazard ratios for 
unit changes in the components of Z holding the exposure and other components 
of Z constant at any level. The baseline function can take any shape the shape of 
the hazard function over time). Another assumption is that the hazard ratio 
remains constant during the study follow up i.e. hazards are proportional. 
Compliance with the proportional hazards assumption was examined for the 
main exposure using log – log curves and no obvious violation was seen for 
FEV1 or FVC quartiles. 
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The variables included in the above two studies are shown in Table 7. We 
will examine the incidence density of HF over the course of follow up assuming 
both a Poisson or a negative binomial distribution of events for each race and 
sex groups. 
 
Cox regression models were used to assess the relationship between race 
and gender specific quartiles of FEV1 (and FVC), and airflow obstruction with 
incident HF for each race and gender group. 
 
All Cox models were adjusted for age, height, and squared height 
(height2) since use of percent predicted lung function(s) can violate the 
assumptions of homogeneity of variance required to interpret the estimates 
correctly and has been discouraged, in favor of adjustment using height and 
height2 (22). The potentially strong confounding due to cigarette smoking was 
addressed by stratified analysis by smoking for each race and gender group. 
Further, models were adjusted for prevalent CHD and its traditional risk factors. 
As chronic inflammation may be an intermediary for this association, a change in 
the magnitude of the estimates after additional adjustment for pro-inflammatory, 
pro-coagulability markers and obesity was evaluated. Lastly, adjustment for 
maximum inspiratory pressure was done to adjust for overall decreased muscle 
strength.  
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Multivariable adjusted cumulative failure estimates were plotted by 
quartiles of FEV1, as the inverse of the survival function (1-S (t+0)) to yield the 
estimated cumulative proportion of those who developed heart failure at any time 
point t.  
 
Compliance with the proportional hazards assumption was examined for 
the main exposure using log – log curves and no obvious violation was seen for 
FEV1 or FVC quartiles. 
 
Analysis for Paper II 
Risk scores 
A risk score Z=XBETA could be obtained for each individual in a sample 
by summing the products of regression beta coefficient from a Cox Proportional 
Hazards model regression and individual’s value for that particular variable. The 
beta coefficient can be derived from either an external sample or derived from 
the study sample itself.  
i.e. Zi = Sum (Xai
’ βa),  Zi = risk score for ith individual, Xai is the value of 
Xa risk factor for ith individual and β is regression coefficient for the Xa variable 
from the multivariable model.   
 
 
Discrimination The primary concern of a risk score is its ability to discriminate 
between those who had event from those who did not.  A simple measure of this 
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property is the proportion of HF cases in the highest decile of predicted risk, or 
the ratio of cases in the highest decile to lowest decile or lowest quintile of 
predicted risk. Other commonly used approaches are based on the change in 
area under the curve (AUC) of a ROC curve, or its proxy the c-index for 
classification(Harrell, Lee et al. 1996) as an estimate of the probability that a 
model assigns a higher risk to those who develop HF within the follow-up period 
compared to those who do not. Since closely related, the c-index has limitations 
similar to those of the ROC curves (Graf, Schmoor et al. 1999; Pencina, D' 
Agostino RB et al. 2008).  Among these statistics, AUC is more commonly used 
and understood statistics to examine and compare the discrimination of the 
models.  
 
By taking censoring into consideration, AUC in the context of long term 
risk prediction can be defined as the probability that a person with disease onset 
by time T0 has a higher risk score than a person with no event by time 
T0, )0)(&1)(|( ==> tDtDZZP jiji  where D(t) is an indicator variable for event or 
no event by time t, and Z denotes risk score.3 It is important to restrict to only 
those events occurring at time ≤T0 as estimations below are based on a fitted 
survival function. Chambless, Diao et al provided an estimator of AUC which was 
a function of time, thus  accounted for censoring. Current work based on Gang, 
Chambless et al further modifies extended AUC as probability of one person with 
earlier disease onset by time T0 having higher score than another person with 
later disease onset, )|( 0TTTTZZP ijiji <<> Ι . 
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AUC is the full area estimated giving equal weights to all false positive 
rates. This does not take into account the shape of the ROC curve and thus 
neglects the clinical need of knowing the partial AUC under low false positive 
rates (such as 0-0.2)(McClish 1989). Other measures of separation like PSEP 
(prognostic separation) i.e. predicted probability of HF for the group with worst 
risk score – predicted probability of HF for the group with best risk score(Altman 
and Royston 2000), and SEP (separation) i.e., weighted geometric mean of 
absolute relative risk between a strata and baseline have been described 
(Sauerbrei, Hubner et al. 1997).   
 
In this study we will focus on AUC and novel method as described below.  
Other recent developments consider the net reclassification improvement for 
meaningful cut-offs and integrated discrimination improvement if no risk cut-off 
for decision making exists (Pencina, D' Agostino RB et al. 2008; Pepe, Feng et 
al. 2008). These methods seem more meaningful for clinical decision making 
than c-statistics and also provide much greater power to test incremental 
values(Pencina, D' Agostino RB et al. 2008).  
 
The NRI statistics cross tabulate number of individuals classified into 
various risk levels like low, medium, and high by a basic model and another full 
model. The movement of individual from a category of basic model to a new 
category could be upward, downward, or no movement. Based on individuals 
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actual outcome, the full model may be reclassified him/her appropriately (upward 
movement of someone with event and downward of someone who didn’t had 
event) of inappropriately.  
i.e.,  
0)D | P(Z 1)D | P(ZImproves Model downup =+==             
   
1)D | P(Z 0)D | P(Z WorsensModel downup =+==                                          
 
 
Table 6.  Reclassification of individuals into risk categories by an extended model 
and appropriateness of such reclassification (Adapted from master’s paper of Mr. 
Cui Gang, Biostatistics, UNC, Chapel Hill  
  Extended (Full) Model 
 
  Low Risk Medium Risk High Risk 
Low  
Risk 
Neither 
UP 
Improve if D=1 
Worsen if D=0 
 
UP 
Improve if D=1 
Worsen if D=0 
 
Medium 
Risk 
DOWN 
Worsen if D=1 
Improve if D=0 
 
Neither 
UP 
Improve if D=1 
Worsen if D=0 
B
a
s
ic
 M
o
d
e
l 
 
 
High  
Risk 
DOWN 
Worsen if D=1 
Improve if D=0 
 
        DOWN 
Worsen if D=1 
Improve if D=0 
 
Neither 
 
     
 
The NRI can thus be defined as the probability the full model improves the 
overall risk prediction minus the probability the full model worsens the overall risk 
prediction. 
 
    
 
 
1)]D | P(Z 0)D | [P(Z - 0)]D | P(Z 1)D | [P(ZNRI downupdownup =+==+==
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Calibration To check for goodness of fit to the data comparisons will be made at 
two levels. First, for combinations of predictor variables we will use Hosmer and 
Lemeshow’s delta-chi square influence statistic (the decrease in the Pearson 
goodness of fit statistic that results from deleting the set of observations that 
share a specific covariate pattern) and the Pregibon delta-beta statistic, which 
results from the Pearson residual and the “hat matrix” (Hosmer and Lemeshow 
1999). Second, the overall function’s predicted risks will be used to divide the 
observations into deciles of predicted, compared to observed risk. Plots will be 
constructed showing predicted and actual event rates for each decile (Arjas 
plots) (Gronnesby and Borgan 1996).   
 
The Gronnesby and Borgan statistic (GB-stat) as proposed by Gronnesby 
and Borgan (1996) is a goodness of fit test for the Cox proportional hazard 
model.  By computing the martingale residuals for each decile, the GB-stat tests 
the hypothesis that the expected value of the sum of these residuals is equal to 
zero.   
 
Correction for Optimism in estimate 
 
It is expected that AUC statistics calculated using risk score with beta 
estimates derived from same sample will behave better than AUC derived in an 
external sample. We will use bootstrapping (Harrell, Lee et al. 1996), re-sampling 
from the study sample with replacement, to correct for some of this optimism. We 
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will do 1000 bootstraps using the study sample size. Bootstrapping provides 
stable estimates with lower bias as compared to the other similar methods for 
validation including split-sample, cross-validation (Steyerberg, Harrell et al. 2001) 
and permits using the entire dataset as well as allowing for estimation of the error 
rates or for the reduction of bias of effect estimates. The bias-corrected 
coefficients will be used for comparisons of the estimates. The average optimism 
i.e., (measure bootstrap samples – measure original dataset) will be subtracted from the 
original performance measure to provide a more realistic estimate. 
 
J. Methodological strengths and limitations 
4.6.1 Strengths The ability to use extant data from a large, population-based 
biracial closed cohort with an average of 10 years of follow up provides excellent 
opportunity to address a novel study question with a clear translation potential. 
The availability in this cohort of modern biomarkers related to HF and of 
application in clinical practice and epidemiologic research represents a particular 
strength. The disciplined plan of analyses and methodological rigor contributed 
by the newer analytic and validation tools built into this proposal provide a better-
than-usual assurance against particularistic associations or over-fitting due to 
sparse outcomes (Harrell, Lee et al. 1985). This study will provide a much useful 
external validation to Health ABC study using similar criteria to ascertain 
outcome. For the incremental value of biomarkers, while the study results would 
be internally valid and corrected for optimism replication in other settings and 
populations will be needed.   
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4.6.2 Limitations   Our outcome is incident hospitalized HF, which represents an 
advanced stage of HF requiring hospital admission. Also, these events are not 
validated and rely on ICD codes primary meant for administrative purposes. This 
may be acceptable as the purpose of the study is to aid in the identification of 
individuals at risk at an early stage of the natural history of HF, allowing timely 
diagnosis and proactive management. As there are no set criteria for 
hospitalization of patients presenting with symptoms of HF, the set of variables 
identified may have some restrictions to its generalizability.  
As a further limitation it should be mentioned that information on cardiac 
imaging is not available for a large proportion of cohort, hence type of ventricular 
dysfunction i.e., systolic vs. diastolic is unknown. It should be noted however that 
however that there is little known difference in the signs and symptoms of systolic 
and diastolic HF, leading to our expectation that no appreciable loss of 
discriminatory information will occur in the absence of data on cardiac imaging. 
Since the primary purpose of the HF risk prediction function is to aid in the early 
identification of individuals at risk of HF in primary care settings, recourse to 
cardiac imaging for such a purpose would not be desirable.  Instead, the 
penetration of biomarkers into clinical practice poses the question of their 
putative usefulness in predicting HF risk if considered in the context of 
“established” HF risk prediction equations and the use of simple measures 
commonly used in clinical practice. Lastly, it must be noted that the ARIC cohort 
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does not include Hispanics or Indian Americans in numbers sufficient to perform 
analyses in these groups. 
 Chapter IV 
RESULTS 
A. Manuscript 1: Obstructive airway disease, lung function and 
Incident Heart Failure: the Atherosclerosis Risk in Communities 
(ARIC) Study 
1. Introduction  
 
Heart Failure (HF) is a major cause of disability and premature mortality in 
the U.S. (Rosamond, Flegal et al. 2008). It has a poor prognosis (Levy, 
Kenchaiah et al. 2002), and the cost associated with its treatment exceeds those 
for coronary artery disease and cancer combined, accounting for about 5.4% of 
the total U.S. health care cost (O'Connell and Bristow 1994). Chronic obstructive 
pulmonary disease (COPD) remains the fourth leading cause of morbidity and 
mortality in the U.S. and it is projected to surpass stroke as the third leading 
cause of deaths by 2020 (Jemal, Ward et al. 2005). The estimated direct and 
indirect cost of COPD is $24 billion (1997) in the U.S. (Pauwels, Buist et al. 
2001).  
 
COPD is a common comorbidity among patients with HF, and vice versa 
(Dahlstrom 2005; Rutten, Cramer et al. 2006; Iversen, Kjaergaard et al. 2008), 
(Rutten, Cramer et al. 2005). A large body of literature suggests higher 
cardiovascular mortality in individuals with COPD and low lung volume (Pauwels,
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Buist et al. 2001; Sin, Wu et al. 2005; Mannino, Doherty et al. 2006; McGarvey,  
John et al. 2007).  An overlap of HF and COPD has been alluded to in the 
literature. In patients with COPD the predicted percentage of FEV1 was inversely 
associated with left ventricular ejection fraction(Yilmaz, Gencer et al. 2005) and  
especially severe COPD causes right sided HF or cor-pulmonale (Budev, 
Arroliga et al. 2003) and impaired left ventricular filling (Boussuges, Pinet et al. 
2000; Yilmaz, Gencer et al. 2005; Funk, Lang et al. 2008). Recent studies 
suggests that left ventricular diastolic and systolic dysfunction is frequently seen 
in mild COPD (Sabit, Bolton et al. 2007),  but few studies have examined sub-
clinical or spirometry-based airflow obstruction and incident HF.   
 
To our knowledge there are no population-based reports that 
systematically examine COPD and the risk of incident HF; similarly, little 
information is available on the relationship between pulmonary function and 
incident HF. We hypothesized that low lung function as well as airflow obstruction 
in individuals without HF is associated with increased risk of subsequent HF, and 
that this relationship would be consistent across groups defined by race, gender, 
and smoking status. We addressed these questions in a large biracial cohort of 
men and women in four U.S. communities. 
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2. Methods 
Study population 
The ARIC Study enrolled 15,792 men and women ages 45-64 years 
sampled from four U.S. communities: Forsyth County, NC; Jackson, MS; seven 
northwestern suburbs of Minneapolis, MN; and Washington County, MD.  
Enrollment at the Jackson, MS site was restricted to black residents, while black 
residents were over-sampled in Forsyth County. Baseline examinations of the 
cohort were conducted from 1987 to 1989 to collect standardized information on 
socioeconomic indicators, medical history, family history, cardiovascular risk 
factors, serum chemistries, electrocardiograms (ECGs), medication use, and 
lung volumes.  Three re-examinations followed the baseline visit, as well as 
annual telephone interviews and active surveillance of hospitalizations and 
death.  
Those with prevalent HF (n=775) or missing (n=325) data on HF at 
baseline (Loehr, Rosamond et al. 2008) ;  missing (n=127) or implausible (n=12) 
lung volume data; missing information on important covariates (n=780); race 
other than black or white (n=48) were excluded from these analyses.  The final 
study sample was 13,660. 
Exposure   
Pulmonary function was assessed at the baseline visit (1987-89) using a 
water-sealed Collins Survey II volume displacement spirometer (Collins Medical, 
Inc.) and Pulmo-Screen II software (PDS Healthcare Products,496 Inc.).   
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Spirometry was conducted using American Thoracic Society (ATS) guidelines 
(1987). From at least three acceptable readings, of which at least two were 
reproducible (volumes within ± 5%), a best reading was selected by computer 
software and confirmed by technician using ATS criteria for acceptability. The 
protocol was standardized across four field centers, with training and certification 
of pulmonary technicians and extensive quality assurance throughout the study. 
History of respiratory illness was obtained via standardized questionnaire by 
trained personnel (Ferris 1978). Chronic bronchitis was defined as productive 
cough for at least 3 months in 2 contiguous years. History of respiratory illness 
was determined by asking participants if they were ever diagnosed with 
bronchitis/emphysema/asthma and whether it was confirmed by a doctor. COPD 
was defined by a positive response to either a physician diagnosis of 
emphysema or bronchitis. Also, a FEV1/FVC ratio of less than 0.7 was used to 
define possible obstructive respiratory illness. Those with possible obstructive 
disease by spirometry were further divided into mild (FEV1 ≥ 80% of predicted 
value) and moderate/severe (FEV1 < 80% of predicted) (1995; Pauwels, Buist et 
al. 2001).  
Covariates 
At baseline, prevalent coronary heart disease (CHD) was ascertained by 
self-report and a 12-lead ECG. Hypertension was defined by diastolic pressure≥ 
90 mm Hg or systolic pressure≥140 mm Hg on the average of the last 2 of 3 
measurements, or the use of anti-hypertensive medications. Diabetes was 
defined by the presence of serum glucose level >= 200 mg/dl, an 8-hour fasting 
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glucose level >=126 mg/dl, a self-reported history of physician-diagnosed 
diabetes, or the current use of hypo/antihyper-glycemic medications. Other 
medications intake including beta blockers was self-reported or derived from 
medicines brought by participants during exam. Cigarette smoking status was 
defined as currently smoking or a history of ever smoking four hundred cigarettes 
or more. The average number of cigarettes/day and number of years of smoking 
reported were multiplied to derive cigarette-years of smoking. Body mass index 
was defined as the ratio of measured weight (kilograms) and measured height2 
(in meters2). Participants identified themselves as belonging to 
American/Alaskan Indian, Asian, black, or white race.  
Heart Failure 
Incident HF was defined as the first HF hospitalization with an HF 
discharge code or HF as the underlying cause of death on a death certificate 
(n=84). Hospital discharge diagnoses were coded using the International 
Classification of Diseases Code, Ninth Revision (ICD-9, code 428), and deaths 
were coded using ICD-9 or ICD-10 (codes 428 and I 50, respectively).  Cohort 
follow up for the current analysis ended on 31st December 2004.  
Statistical Methods  
Means (standard deviations) and proportions of characteristics at baseline 
and follow up HF event rates were calculated for quartiles of FEV1. A higher 
proportion of blacks and women were in the lower quartiles of FEV1 and FVC; 
thus all analysis (except for table 7) used race and gender specific quartiles of 
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FEV1. Incidence density (rate) of HF in various strata was estimated assuming a 
Poisson distribution. Cox regression models were used to assess the relationship 
between race and gender specific quartiles of FEV1 (and FVC), and airflow 
obstruction with incident HF for each race and gender group. 
 
All Cox models were adjusted for age, height, and squared height 
(height2) since use of percent predicted lung function(s) can violate the 
assumptions of homogeneity of variance required to interpret the estimates 
correctly and has been discouraged, in favor of adjustment using height and 
height2 (Vollmer, Johnson et al. 1987). The potentially strong confounding due to 
cigarette smoking was addressed by stratified analysis by smoking for each race 
and gender group. Further, models were adjusted for prevalent CHD and its 
traditional risk factors. As chronic inflammation may be an intermediary for this 
association, a change in the magnitude of the estimates after additional 
adjustment for pro-inflammatory, pro-coagulability markers and obesity was 
evaluated. Lastly, adjustment for maximum inspiratory pressure was done to 
adjust for overall decreased muscle strength.  
 
Multivariable adjusted cumulative failure estimates were plotted by 
quartiles of FEV1, as the inverse of the survival function (1-S (t+0)) to yield the 
estimated cumulative proportion of those who developed heart failure at any time 
point t. To evaluate the potential influence of a misdiagnosis of incident HF on 
studied association, additional sensitivity analysis were done, (a) by excluding 
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those with baseline COPD, CHD, or both and (b) by censoring HF events with a 
concomitant discharge code for acute exacerbation of COPD, respiratory failure, 
or both. Detailed methods and results of the sensitivity analysis are reported in 
the footnote to online Supplemental Table 7. Compliance with the proportional 
hazards assumption was examined for the main exposure using log – log curves 
and no obvious violation was seen for FEV1 or FVC quartiles. SAS, version-9.1 
and STATA-IC, version-10 software were used for analysis. A p<0.05 for a two-
sided test was considered statistically significant.  
 
Results 
A total of 1369 (10%) participants developed HF over the average follow-
up of 14.9 years. Characteristics of all study participants by decreasing gender-
specific quartiles of FEV1 are shown in Table 7.  At study baseline, those in the 
lower quartiles of FEV1 had a higher mean age, cigarette-years of smoking, 
systolic blood pressure, markers of inflammation, a lower height, and a higher 
proportion were current smokers, black, women, or had respiratory illness.  The 
25th, 50th, and 75th percentiles of FEV1 in liters were 1.9, 2.2 and 2.5 in black 
females; 2.6, 3.0, and 3.4 in black males; 2.2, 2.5, and 2.8 in white females; 3.0, 
3.5, and 3.9 in white males.  
 
A monotonic increase in the rate of incident HF with decreasing quartile of 
FEV1 was seen in both blacks and whites, after adjusting for age, and height 
(Figure 1). The age and height adjusted average incidence rates of HF per 1000 
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person year by quartiles of FEV1 were – from highest to lowest quartile – 14.7 , 
8.2, 5.1, and 2.9  for blacks, and 11.8, 6.6, 4.1, and 2.3 for whites.  
 
In Cox regression models adjusted for age, smoking, and height, the 
hazard ratios (HRs) of HF increased monotonically and inversely by quartiles of 
FEV1, for both genders in each race group (Figure 2). The age and height 
adjusted HRs and their 95% confidence interval (95%CI) contrasting those in the 
lowest quartile of FEV1 to those in highest for HF were 3.48 (2.24, 5.40) among 
black female, 2.88 (1.80, 4.61) among black males, 6.95 (4.42, 10.94) among 
white female, and 5.66 (4.04, 7.91) among white males. The HRs comparing the 
highest to lowest quartile were of greater magnitude in whites than in blacks, and 
in women than in men, and were statistically significant for all contrasts to the 
highest quartile except for third quartile among black males. In similar models, 
HR estimates were slightly higher when contrasting quartiles of FVC (data not 
shown) than FEV1. 
 
The above associations were observed across all smoking status 
categories. Among never smokers, the age, height, height2 adjusted HF hazard 
rate estimate was about 2.5 to 3 times higher those in the lowest quartile of FEV1 
than in the highest (Table 8).  
 
In multivariable models adjusted for age, height, prevalent CHD, and 
traditional cardiovascular risk factors the HRs (95% CI) contrasting the lowest 
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with the highest quartiles of FEV1 were 2.91 (2.14, 3.97) for women and 2.23 
(1.69, 2.93) for women (Table 8). On further adjustment for covariates including 
prevalent CHD and traditional cardiovascular risk factors, body mass index, white 
blood cell count, fibrinogen, Von-Willebrand’s factor and serum albumin, the 
magnitude of the hazard ratios were attenuated slightly, although they remained 
statistically significant for all race and gender group (Table 8). The multivariable 
adjusted cumulative risk of incident HF by quartiles of FEV1 is shown in Figure 3. 
They show a graded increase in the risk of HF for decreasing quartiles of FEV1 
throughout the study period.  
 
In multivariable adjusted models, the hazard ratios for HF contrasting 
those with FEV1/FVC <70% to those with ≥70% were 1.44 (1.20, 1.74) and 1.40 
(1.13, 1.72) for women and men, respectively (Table 9). Of note, the severity of 
COPD was predictive as spirometry-defined mild COPD was not associated with 
incident HF.  On testing associations of several definitions of respiratory illness 
with incident HF, a self-reported physician diagnosis of emphysema had the 
strongest association with incident HF in both men and women, whereas self-
reported physician diagnosis of asthma had a weak association in women, and 
no association in men (Table 9). Self-reported COPD was similar to spirometry-
defined COPD in its association with incident HF.  For example, the HR (95% CI) 
comparing those with a self reported diagnosis of COPD than those without were 
1.84 (1.47, 2.31) for women and 1.44 (1.08, 1.91) for men.  
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Discussion 
We observed a strong inverse association between baseline lung function 
with incident HF, and a monotonic, direct association between airflow obstruction 
and incident HF. These associations were seen across groups defined by race, 
gender, and smoking status. Notably, the relationship was seen in never-
smokers and after adjustment for smoking status and cigarette-years of smoking, 
indicating that our results are not primarily confounded by smoking.  
 
These results in a population-based cohort are consistent with clinical 
observations, but also with two prior reports from population based cohorts, 
indicating that a low FEV1 was strongly predictive of HF, independent of many 
traditional and non-traditional risk markers (Eriksson, Svardsudd et al. 1989; 
Gottdiener, Arnold et al. 2000). The present study extends these results by the 
length and completeness of its follow-up, a replication in African Americans, and 
by examination of markers of chronic inflammation a potential mechanism,.  
 
We also found a consistent association of interviewer-ascertained chronic 
bronchitis, self reported COPD and emphysema, and airway obstruction 
(FEV1/FVC<70%) with incident HF, but not with asthma. The weak but 
statistically significant association of asthma with incident HF among women 
could be explained by misdiagnosis of COPD for asthma in primary care, 
reportedly more common in women than in men (Chapman, Tashkin et al. 2001). 
Our results are similar to those of a large retrospective case control study based 
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on claims data, where COPD was associated with an almost threefold higher rate 
of HF hospitalization (Sidney, Sorel et al. 2005), although the magnitude of that 
association was of considerably greater magnitude than seen in this study.  
Rates of heart failure and other CVD related hospitalizations were also reported 
to be higher in those with COPD as compared to the general population of 
Canada (Huiart, Ernst et al. 2005). Further, these associations were seen with 
moderate/severe COPD (defined with spirometry) and not with mild disease. The 
only other population based study to examine the association of low FEV1/FVC 
(<60% vs. higher) with HF events did not find an association (Kannel, Seidman et 
al. 1974), although limited statistical power is a likely explanation for the 
observed lack of effect.  
 
Several traditional cardiovascular risk factors are associated with both low 
lung function and HF, and thus could confound the associations reported here. 
Both FVC and FEV1 show an inverse association with blood sugar, blood 
pressure, serum cholesterol, BMI and left ventricular mass(Kannel, Hubert et al. 
1983; Enright, Kronmal et al. 1995; Enright, McClelland et al. 2001; Gunnell, 
Whitley et al. 2003). Our estimates were somewhat attenuated after adjustment 
for these putative confounding variables, but they remained statistically 
significant (Table 8-9). It has been reported that lower lung volumes may be seen 
in HF patients with large heart size due to lung impingement(Agostoni, Cattadori 
et al. 2000; Olson, Beck et al. 2006). This is unlikely to be common in a 
population sample of middle-aged individuals without HF at study baseline; 
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moreover, statistical adjustment for left ventricular mass estimated by the Cornell 
voltage did not change the magnitude of our estimates.  Overweight and obesity 
were considered as possible confounders.  However, no clear patterns of 
association between ponderosity and lung function or respiratory disease were 
seen in these data however, and statistical adjustment for BMI did not change 
our results appreciably.  
 
Levels of systemic markers of inflammation are higher in those with low 
lung volumes, and links between inflammation and HF have been proposed 
(Gunnell, Whitley et al. 2003; Barnes 2007). These high levels may reflect either 
spill of inflammatory markers from inflammation localized to the lungs or an 
upstream up-regulation of inflammatory cascade. (Barnes and Celli 2009). We 
observed some attenuation of the HR estimates in our study after adjustment for 
baseline levels of inflammatory makers, which lends some support to the 
inflammation-HF hypothesis. Beyond those observed in cigarette smokers, 
declines in lung volumes may also be seen with a higher exposure to road traffic 
(Kan, Heiss et al. 2008) with and diabetes (Yeh, Punjabi et al. 2008). However, it 
is far from established whether the risk of HF is influenced by the latter two 
characteristics. Exercise training appears to improve physical function in both 
COPD and HF – primarily by improving skeletal muscle function – but possibly by 
reducing inflammation as well (Coats 1999; Celli and MacNee 2004).  Whether it 
can prevent HF in COPD patients needs evaluation.  
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Kannel et al. suggested that decreased muscle strength may partially 
account for the inverse association of FEV1 with HF (Kannel, Seidman et al. 
1974). Statistical adjustment for maximum inspiratory pressure, a measure of 
respiratory muscle strength, indeed attenuated the magnitude of our results. For 
reasons that are not obvious this attenuation was of greater magnitude in the 
black members of the ARIC cohort. We also examined the potential confounding 
bias introduced by the use of beta blockers but did not see evidence of 
confounding (data not shown).  
 
Some of the traits mentioned above as covariates and potential 
intermediaries may be associated with HF directly or indirectly through their 
association with CHD. For instance, low FVC is associated with incident 
diabetes(Yeh, Punjabi et al. 2005), sub-clinical atherosclerosis (Schroeder, 
Welch et al. 2005), arterial stiffness (Bolton, Cockcroft et al. 2009), and incident 
ischemic heart disease (Cook and Shaper 1988; Marcus, Curb et al. 1989; 
Engstrom, Lind et al. 2002; Schroeder, Welch et al. 2003). Empirically, excluding 
those with prevalent CHD at baseline did not visibly change the results (Table 
10).  
 
Misclassification of hospitalized COPD exacerbations as HF is 
conceivable given the many overlapping signs and symptoms(Hawkins, Petrie et 
al. 2009), and that the HF events in this study were not validated by chart review.  
An ICD code- 428.x has a positive predictive value of 94.3% when compared to 
  57 
Framingham criteria (Lee, Donovan et al. 2005), and 83.0% compared to a 
physician diagnosis and pulmonary edema on chest X-ray(Goff, Pandey et al. 
2000).To evaluate whether our findings may be a result of misclassification of 
incident HF sensitivity analyses were conducted as stated in the methods 
section. The estimated associations didn’t change appreciably following 
exclusion of COPD at baseline, or by censoring those with concurrent COPD and 
HF (Table 10). Lastly, a decreased lung function may contribute to early 
exacerbation of asymptomatic ventricular dysfunction and possibly to lead-time 
bias. Given the strength of the estimates observed and the almost constant 
hazard ratio estimates over time, if present these biases are unlikely to have an 
effect that would alter the inferences presented here. 
 
Several limitations of this study should be mentioned. The most important 
among them is the lack of validation and detailed characterization of the heart 
failure events. Further, respiratory symptoms and diagnoses were self reported 
and not validated.  Perhaps less worrisome, smoking status was self reported 
and not validated with biomarkers, thus some residual confounding due to 
smoking could not be ruled out, and neither post bronchodilator lung function or 
total lung volume were measured. Lastly, although adjustment for BMI did not 
influence the estimates, residual confounding due to sleep apnea could not be 
ruled out. The strengths of our findings include their prospective and population-
based nature, their internal consistency including among non-smokers, the 
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sizeable magnitude of hazard ratio estimates even after multivariable adjustment, 
and the imperviousness of the results to various sensitivity analyses.  
 
Studies are needed that can address the associations reported here with 
further characterization of HF into systolic and diastolic phenotypes. Whether 
improvement (or a slower decline) in lung function with smoking 
cessation(Scanlon, Connett et al. 2000), increased physical activity(Garcia-
Aymerich, Lange et al. 2007) or other novel interventions is related to future risk 
of HF similarly need attention. In a population based study, CT scan-defined 
emphysema, and spirometry-defined airflow obstruction were linearly associated 
with impaired ventricular filling, and reduced cardiac output but not with ejection 
fraction (Barr et al, Left ventricular filling in emphysema and airflow obstruction; 
unpublished). A recently reported large burden on unrecognized heart failure in 
patients with COPD (Rutten, Cramer et al. 2005) further suggests that more 
attention to HF in individuals with COPD is warranted. An enhanced 
understanding of the pathophysiologic changes in heart structure and function in 
the context of COPD would be similarly important. 
 
An increase in pulmonary vascular resistance, pulmonary artery pressure, 
lower pulmonary vessel endothelial function, and endothelial proliferation in 
pulmonary vasculature is seen with alveolar hypoxia and in individuals with even 
mild/moderate COPD (Santos, Peinado et al. 2002; Santos, Peinado et al. 2003; 
Budhiraja, Tuder et al. 2004; Han, McLaughlin et al. 2007; Barnes and Celli 
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2009). It seems reasonable to think that such changes may manifest in early right 
ventricular structural (Vonk-Noordegraaf, Marcus et al. 2005) and functional 
abnormalities that could ultimately lead to a deterioration of left ventricular 
function and clinical HF due to inter-ventricular dependence (Vonk Noordegraaf, 
Marcus et al. 1997). Several other systemic mechanisms such as systemic 
inflammation (Schroeder, Welch et al. 2003),  autonomic dysfunction (Undem 
and Kollarik 2005), oxidative stress (Mannino, Doherty et al. 2006),  chronic 
muscle wasting (Barnes and Celli 2009) have been implicated to result in new-
onset HF in individuals with COPD. Further, animal studies show an increased 
right sided heart injury with increased end expiratory volume as seen in acute 
exacerbation of COPD (Simpson, Brunt et al. 2009). 
 
In conclusion, in this large population based closed cohort study with long 
term follow up, we observe that low FEV1, low FVC, self reported COPD, and 
airway obstruction are associated with incident HF.  
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Table 7. Characteristics of study participants at baseline and incident heart failure across 
quartiles of FEV1 (N=13360) 
 
 
FEV1 quartile at baseline† 
Characteristic* 
Q1(0.5 - 2.3 
L) 
n=3415 
Q2 (2.3 – 2.8 
L) 
n=3415 
Q3(2.8 - 3.3 
L) 
n=3415 
Q4 (3.3 - 5.9 
L) 
n=3415 
Demographic/Lifestyle/Clinic
al          
Age (in years) 56.06 5.61 54.15 5.7 53.45 5.73 52.62 5.4 
Male 14.6  21.5  51.2  93.3  
African American 39.1  27.2  20.6  11.6  
Hypertension 41.8  31.7  29.7  23.5  
Diabetes 15.1  9.6  9.4  7.4  
Current smoker 36.5  25.3  21.6  17.7  
Former Smoker 21.3  26.6  34.7  44.8  
Cigarette-years of smoking 361.6 467.9 269.0 397.5 305.6 434.5 307.9 386.3 
Usual ethanol intake (in 
grams/week) 27.9 82.3 31.2 75.6 49.1 107.1 62.6 106.3 
Height (in centimeters) 161.9 7.5 164.8 7.1 169.9 7.3 177.6 6.5 
Systolic blood pressure (in mm 
of Hg) 124.9 20.4 120.1 18.4 119.4 18.1 118.4 15.6 
Diastolic blood pressure (in 
mm of Hg) 73.2 11.8 72.6 10.9 73.5 11.0 74.4 10.3 
LDL cholesterol (in mg/dL) 139.4 42.0 136.2 38.4 136.3 38.8 138.2 36.6 
HDL cholesterol (in mg/dL) 55.4 17.7 55.4 16.9 52.2 17.4 45.5 13.8 
Body Mass Index (in kg/meter
2 
) 28.2 6.4 27.4 5.5 27.1 4.9 27.2 3.7 
  Inflammatory Markers         
White blood count (x 10
3
/mm
3
) 6.4 2.1 6.0 1.9 6.0 1.8 5.9 2.1 
Fibrinogen (mg/dl) 322.4 71.0 302.0 61.3 297.0 61.6 284.5 55.9 
Albumin (in g/dL) 3.2 0.7 3.2 0.6 3.1 0.6 3.1 0.6 
Von-Willebrand's Factor (%) 126.1 53.2 117.1 46.6 114.1 44.2 110.0 42.6 
   Study Exposure(S)         
Forced Expiratory Volume (1s, 
in L) 1.9 0.3 2.5 0.1 3.0 0.2 3.9 0.4 
Forced Vital Capacity (in 
Liters) 2.8 0.5 3.4 0.4 4.0 0.4 5.1 0.6 
FEV(1)/FVC 70.8 11.0 75.1 6.8 75.6 6.4 76.3 5.4 
FEV1/FVC <70%  41.1  22.5  20.6  15.8  
Chronic bronchitis
¶ 
  7.6  4.1  4.3  3.8  
Self reported diagnosis of 
bronchitis 13.3  6.9  5.3  3.7  
Self reported diagnosis of 
emphysema 3.7  0.9  0.8  0.7  
Self reported diagnosis of 
COPD
||
 15.4  7.5  5.9  4.3  
Self reported diagnosis of 
asthma 8.5 
 
4.3 
 
4.2  3.5 
 
  Follow up         
Heart Failure events 16.2  9.3  8.3  6.3  
  67 
Follow up duration (in years) 14.0 4.3 15.1 3.4 15.1 3.3 15.4 3.0 
Heart failure rate/1000 person 
years 11.5  6.1  5.5  4.1  
*
Expressed as Mean and Standard deviation (SD) or Percentages 
FEV1 = Forced Expiratory Volume during 1
st
 second measured using standardized spirometry at 
study baseline. Data from the Atherosclerosis Risk in Communities (ARIC) Study baseline 
examination (1987-89) in a sub-sample without prevalent heart failure and non missing 
information on important covariates, followed through December 31, 2004.   
¶
Chronic bronchitis was defined as productive cough for at least 3 months in 2 contiguous years;  
||
Self-reported diagnosis of Chronic Obstructive Pulmonary Disease (COPD) is presence of either 
self reported diagnosis of bronchitis or emphysema. 
  
Table 8. Hazard ratios of HF contrasting the lowest and highest quartiles of FEV1 by incremental level of 
covariate adjustments (N = 13360)  
  
 
White participants 
(N = 10293, n = 927) 
Black participants 
(N=3367, n = 442) 
 
All Participants 
(N=13360, n=1369) 
Gender 
Smoking 
status/ Model HR (95% CI) HR (95% CI) 
 
HR (95% CI) 
           
Women Current* 9.87 (3.01, 32.34) 3.56 (1.50, 8.49) 4.94 (2.50, 9.76) 
 Former* 4.35 (1.65, 11.50) 2.99 (1.13, 7.80) 4.27 (2.13, 8.53) 
 No* 3.88 (2.03, 7.42) 3.01 (1.63, 5.56) 4.01 (2.57, 6.27) 
          
 Model 1† 4.80 (3.00, 7.68) 2.98 (1.91, 4.66) 4.12 (2.98, 5.70) 
 Model 2‡ 3.91 (2.40, 6.35) 2.11 (1.33, 3.34) 2.91 (2.14, 3.97) 
 Model 3§ 3.61 (2.21, 5.88) 2.00 (1.25, 3.19) 2.44 (1.79, 3.34) 
 Model 4# 3.44 (2.03, 5.83) 1.61 (0.95, 2.72) 2.19 (1.54, 3.12) 
          
Men Current* 2.51 (1.31, 4.81) 2.71 (1.25, 5.88) 2.42 (1.48, 3.97) 
 Former* 6.72 (4.07, 11.08) 2.91 (1.23, 6.88) 5.60 (3.65, 8.60) 
 No* 3.04 (1.46, 6.31) 2.44 (0.94, 6.33) 2.94 (1.65, 5.22) 
          
 Model 1† 4.11 (2.89, 5.84) 2.55 (1.57, 4.13) 3.51 (2.65, 4.66) 
 Model 2‡ 3.03 (2.12, 4.33) 2.23 (1.37, 3.59) 2.23 (1.69, 2.93) 
 Model 3§ 2.98 (2.07, 4.28) 2.11 (1.30, 2.41) 1.92 (1.44, 2.55) 
 Model 4# 2.68 (1.83, 3.92) 1.72 (0.96, 3.07) 1.80 (1.32, 2.44) 
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N = study sample size, n = incident HF cases; FEV1 = Forced Expiratory Volume (1second) 
Data from the Atherosclerosis Risk in Communities (ARIC) Study baseline examination (1987-89) in a 
sub-sample without prevalent heart failure and non missing information on important covariates, followed 
through December 31, 2004. 
FEV1 quartiles were race and gender specific, and the models contained quartiles as indicator variables 
to estimate the effect size without assuming log-linearity in FEV1 quartiles. Estimates are reported only 
contrasting the lowest with highest quartile of FEV1. 
Each of the hazard ratio (HR) and its 95% confidence interval (95% CI) is from a separate model. For 
smoking categories, subset analysis was done by running separate models for each smoking stratum for 
each race and gender.  * Hazard ratios and 95% confidence interval, adjusted for age, height, height2. 
Further models with adjustment for incremental level of covariates were 
†Model 1: In addition to age, height, height*height, this model additionally adjusts for current smoking 
status by using two binary variables: current smoking, and former smoking, and Cigarette-years of 
smoking. 
‡Model 2: In addition to model 1 covariates, this adjusts for prevalent coronary heart disease, diabetes, 
hypertension, LDL cholesterol and HDL cholesterol. 
§Model 3: In addition to model 2 covariates, this adjusts for fibrinogen levels, white blood count, Von-
Willebrand's factor, and serum albumin and body mass index. 
#Model 4: In addition to model 3, this adjusts for maximum inspiratory pressure measured during visit 2 (3 
years after baseline visit), with fewer observations (Whites n= 9027, Blacks n= 2820) 
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Table 9. Hazard ratios of HF for airway obstruction, and self reported diagnosis of respiratory illness.       
( N = 13130) 
  Model 1
†
  Model 2
‡
 
Men   HR (95% CI)*  HR (95% CI)* 
 COPD vs. no COPD by spirometry 1.61 (1.36, 1.91)  1.44 (1.20, 1.74) 
     Mild COPD vs. no COPD by spirometry 0.90 (0.69, 1.18)  0.98 (0.74, 1.29) 
 
    Moderate/severe COPD vs. no COPD by 
spirometry 2.30 (1.90, 2.77) 
 
1.83 (1.49, 2.26) 
 Chronic bronchitis
¶ 
  2.07 (1.60, 2.69)  1.42 (1.03, 1.98) 
 Self reported diagnosis of bronchitis 1.65 (1.20, 2.27)  1.44 (1.04, 2.00) 
 Self reported diagnosis of emphysema 2.22 (1.51, 3.25)  1.85 (1.23, 2.77) 
 Self reported diagnosis of COPD
||
 1.70 (1.30, 2.20)  1.44 (1.08, 1.91) 
 Self reported diagnosis of asthma 1.06 (0.74, 1.51)  1.15 (0.80, 1.64) 
       
Women       
 COPD vs. no COPD by spirometry 1.40 (1.15, 1.71)  1.40 (1.13, 1.72) 
     Mild COPD vs. no COPD by spirometry 0.90 (0.67, 1.20)  1.07 (0.79, 1.45) 
 
    Moderate/severe COPD vs. no COPD by 
spirometry 2.09 (1.65, 2.65) 
 
1.73 (1.34, 2.22) 
 Chronic bronchitis
¶ 
  2.11 (1.54, 2.99)  1.74 (1.34, 2.19) 
 Self reported diagnosis of bronchitis 2.27 (1.83, 2.82)  1.84 (1.84, 5.28) 
 Self reported diagnosis of emphysema 4.41 (2.72, 7.16)  3.12 (2.11, 5.93) 
 Self reported diagnosis of COPD
||
 2.40 (1.94, 2.96)  1.84 (1.47, 2.31) 
 Self reported diagnosis of asthma 1.60 (1.17, 2.17)  1.56 (1.14, 2.13) 
7
0
 
 HR = Hazard ratio, CI = Confidence Interval, COPD = Chronic Obstructive Pulmonary Disease,  
Data from the Atherosclerosis Risk in Communities (ARIC) Study baseline examination (1987-89) in a sub-sample without 
prevalent heart failure and non missing information on important covariates followed through December 31, 2004. Using 
spirometry, any COPD was defined as FEV1/FVC <70%,   mild COPD was defined as FEV1/FVC (<70%) and FEV ≥ 80% 
(predicted) and moderate/severe COPD as FEV1/FVC (<70%) and FEV < 80% (predicted), and no COPD as FEV1/FVC ≥ 
70%.   
 
†
Model 1 is adjusted for age and race; 
‡ 
Model 2 is adjusted for age, smoking status, cigarette-year of smoking, hypertension, diabetes, LDL-c, HDL-c, body mass index;
¶
Chronic bronchitis was defined as productive cough for at least 3 months in 2 contiguous years;  
||
Self-reported diagnosis of Chronic Obstructive Pulmonary Disease (COPD) is presence of either self reported diagnosis 
of bronchitis or emphysema. 
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Figure 4. Estimated rate of new-onset heart failure per 1000 person years among 
black and white cohort members during an average study follow up of 14.9 years 
by gender and race-specific quartiles of forced expiratory volume, 1s (FEV1). The 
estimated rates are adjusted for age, height and height*height. The estimated rates 
shown are for an individual 55 years of age, and 5.5 feet height.  
 
Data from the Atherosclerosis Risk in Communities (ARIC) Study baseline 
examination (1987-89) in a sub-sample without prevalent heart failure and non 
missing information on important covariates, followed through December 31, 2004.  
P-Y = person years.  
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Figure 5.  Estimated hazard ratio (95% confidence intervals) of incident heart failure 
for the quartiles of forced expiratory volume (1s) for each gender and race, adjusted 
for age, smoking, height, and height*height. Y axis is plotted on a log scale with 
base 2.  
 
Data from the Atherosclerosis Risk in Communities (ARIC) Study baseline 
examination (1987-89) in a sub-sample without prevalent heart failure and non 
missing information on important covariates, followed through December 31, 2004. 
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Figure 6. Multivariable adjusted cumulative-events estimates for incident  
heart failure by quartiles of forced expiratory volume (1s) i.e., Q1 to Q4 
 
Adjusted for age, gender, race, height, height*height, prevalent CHD, diabetes, 
hypertension, cigarette smoking status, cigarette-years years of smoking, LDL 
cholesterol, HDL-cholesterol, and body mass index The curves are statistically not 
similar, using log rank test (p<0.001).  
 
Data from the Atherosclerosis Risk in Communities (ARIC) Study baseline 
examination (1987-89) in a sub-sample without prevalent heart failure and non 
missing information on important covariates, followed through December 31, 2004. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data from the Atherosclerosis Risk in Communities (ARIC) Study baseline examination (1987-89) in a sub-sample without prevalent heart failure 
and non missing information on important covariates, followed through December 31, 2004.  
Hazard ratios and 95% confidence of incident HF contrasting the lowest quartile to the highest quartile of FEV1. FEV1 quartiles were race and 
gender specific, and the models contained quartiles as indicator variables to estimate the effect size without assuming log-linearity in FEV1 
quartiles. The exclusions were made before making the quartiles of FEV1, except in the case where manipulation to index hospitalization events 
was done.  
†Model 1: This model adjusts for age, height, height*height and smoking status by using two binary variables: current smoking, and former smoking, 
and cigarette-years of smoking. 
‡Model 2: In addition to model 1 covariates, it adjusts for prevalent coronary heart disease, diabetes, hypertension, LDL cholesterol and HDL 
cholesterol.  
Acute exacerbation of COPD was defined by the presence of ICD -9 code = 491.21 at any position in the discharge diagnosis or a mention in the 
medical record. Similarly, respiratory failure or insufficiency was defined by the presence of ICD- 9 code = 517.3, 518.5, 518.81, 518.82, 518.83, 
518.84, 799.1, V461, V4611, V4612, V4613, V4614, or V462 at any position in the discharge diagnosis or a mention in the medical record. 
Table 10. Sensitivity analysis of a ratio estimate for association between FEV1 and incident HF : The ARIC study 
Changes made  Model 1 Model 2 
 Female Male Female Male 
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
None (copied from Table 8) 4.12 
(2.98, 
5.70) 
3.51 
(2.65, 
4.66) 
2.91 
(2.14, 
3.97) 
2.23 
(1.69, 
2.93) 
Change the baseline cohort         
Exclude participants with self reported COPD  4.00 
(2.82, 
5.68) 
3.29 
(2.46, 
4.42) 
2.92 
(2.05, 
4.48) 
2.48 
(1.83, 
3.33) 
Exclude participants with prevalent CHD 4.04 
(2.89, 
5.65) 
3.06 
(2.25, 
4.16) 
3.07 
(2.18, 
4.24) 
2.63 
(1.93, 
3.58) 
Exclude both baseline COPD & prevalent CHD 3.99 
(2.77, 
5.69) 
2.86 
(2.08, 
3.95) 
2.95 
(2.04, 
4.27) 
2.44 
(1.77, 
3.37) 
Change the outcome definition         
Exclude those with acute exacerbation of COPD  
 (n=  78) during HF hospitalization  
3.95 
(2.85, 
5.48) 
3.37 
(2.53, 
4.51) 
2.83 
(2.02, 
3.96) 
2.52 
(1.86, 
3.83) 
Exclude those with acute exacerbation of COPD or 
respiratory failure (n=229) during HF hospitalization  
3.99 
(2.82, 
5.63) 
3.47 
(2.55, 
4.72) 
2.77 
(1.95, 
3.94) 
2.56 
(1.87, 
3.49) 
Censor those with acute exacerbation of COPD or  
respiratory failure (n=229) during HF hospitalization   
3.94 
(2.79, 
5.56) 
3.40 
(2.50, 
4.62) 
2.70 
(1.90, 
3.84) 
2.52 
(1.85, 
3.44) 
  
7
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B. Manuscript 2: Optimal prediction of heart failure in community 
settings: The Atherosclerosis Risk in Communities (ARIC) Study  
Introduction  
Each year about 500,000 individuals are diagnosed with Heart Failure (HF) for the 
first time in the U.S. (Rosamond, Flegal et al. 2008). Despite improvements in medical 
management and advances in therapy, the incidence and prevalence of HF have increased 
(Roger, Weston et al. 2004). While there has been progress in the therapy of HF leading to 
better survival during the last decades, many agree that greater efforts need to be directed 
towards early detection of ventricular dysfunction and prevention of symptomatic heart 
failure (Fonseca 2006). Early and accurate HF diagnosis can be viewed as the cornerstone 
of improved patient outcome (Fonseca 2006). 
 
While most patients with HF present for the first time to general practitioners (GPs) 
and are mostly managed by them (Fowler 1997), the importance of early diagnosis and 
treatment of LV systolic dysfunction is not fully appreciated among general practitioners 
(Mair and Bundred 1996). A lack of confidence among primary care physicians in 
establishing an HF diagnosis has been reported as one of the main barriers to providing 
standard care to patients with HF in the community (Fuat, Hungin et al. 2003). To facilitate 
early diagnosis appropriate risk stratification tools may aid in timely referrals and appropriate 
diagnostic tests. Risk prediction from information easily available to primary care physicians 
is one such tool(Kannel, D'Agostino et al. 2004).  
 
The HF risk score function derived in the Framingham Heart Study (Kannel, 
D'Agostino et al. 1999), and a recently published HF risk score from the Health, Aging, and 
  77 
Body Composition(Butler, Kalogeropoulos et al. 2008) study are two extant functions.  
External validation in an independent test data set is considered a requisite before the use 
of such models can be recommended (Ripley 1996). This study examined the external 
validity of the above risk scores in a large, bi-racial cohort of middle aged participants 
sampled from four US communities. We also optimized a HF risk function in the ARIC 
cohort that considers additional characteristics commonly available in primary care settings 
and examined its performance relative to the Framingham and Health ACC functions in the 
prediction of 10-year risk of HF. Lastly, the incremental value to HF risk prediction of 
biomarkers recently found to be predictive of HF was examined since their use in clinical 
settings is increasing. Thus, our aims were to examine the external validity of two extant HF 
risk functions and to compare their performance to one derived in a community based 
sample of middle-aged adults, based on elements easily available to primary care providers.  
 
Methods 
Study population 
The ARIC Study enrolled 15,792 men and women ages 45-64 years sampled from 
four U.S. communities: Forsyth County, NC; Jackson, MS; seven northwestern suburbs of 
Minneapolis, MN; and Washington County, MD.  Enrollment at the Jackson, MS site was 
restricted to black residents, while black residents were over-sampled in Forsyth County. 
Baseline examinations of the cohort were conducted from 1987 to 1989 to collect 
standardized information on socioeconomic indicators, medical history, family history, 
cardiovascular risk factors, serum chemistries, electrocardiograms (ECGs), medication use, 
and lung volumes.  Three re-examinations followed the baseline visit, as well as annual 
telephone interviews and active surveillance of hospitalizations and death. The last 
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complete cohort visit was done in 1996-98. Several biomarkers were assayed from stored 
specimens from this last visit. A complete description of the ARIC communities and of the 
study design has been published [18]. 
 
Analysis involved use of covariates at two different index visits i.e., the baseline 
examination (1987-89) and the third re-examination or visit 4 (1996-98). For analyses using 
baseline data those with prevalent HF (n=775) or missing (n=325) data on HF at baseline 
(Loehr, Rosamond et al. 2008); missing information on any of the predictors shown in table 
11 (n=1502); or race other than black or white (n= 48) were excluded,. thus  leaving a 
cohort of 13,555 observations for analysis. From the 11,751 cohort members examined at 
the ARIC field centers during visit 4, those with prevalent HF at baseline visit (n= 622) and 
those with incident HF between baseline visit and visit 4 (n = 230) were excluded ; those not 
self-identified as black or white (n=30), and those missing any important covariate (n = 237) 
were excluded from the analyses using visit 4 as the index visit. This resulted in  9,144 
study participants for these analyses.  
 
Baseline data 
Participants were requested to refrain from smoking and from consuming caffeinated 
beverages, and to fast for 12 hours before the field center visit.  During the baseline visit 
participants were interviewed, an electrocardiogram was recorded, blood sample obtained 
and a physical exam was performed.   
 
Predictors of heart failure Prevalent coronary heart disease (CHD) was ascertained using 
history elements as well as adjudicated baseline ECG. Following 5 minutes of rest and while 
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seated, blood pressure was measured three times using a random-zero 
sphygmomanometer and an average of the last 2 readings was taken.  Hypertension was 
defined as diastolic pressure≥ 90 mm Hg or systolic pressure≥140 mm Hg on the average of 
the last two of three seated, measurements, or by a self-reported use of medications for 
hypertension. Serum glucose was measured using hexokinase method. Diabetes was 
defined by the presence of any serum glucose level >= 200 mg/dl, an 8-hour fasting glucose 
level >=126 mg/dl, a self-reported history of diabetes, or the current use of medications for 
diabetes. Cigarette smoking status was defined as self reported current smoking or a history 
of ever smoking four hundred cigarettes or more. The self reported average number of 
cigarettes/day and numbers of years of smoking were multiplied to derive cigarette-years of 
smoking and this number was divided by 20 to get pack-years of smoking. COPD was 
defined as a self report of physician diagnosis of either emphysema or chronic bronchitis (or 
a chronic lung disease when using visit 4 as baseline). Body mass index was defined as the 
ratio of measured weight (in kilograms) and measured height2 (in meter2). Participants 
identified themselves as belonging to American/Alaskan Indian, Asian, black, or white race.  
 
An auscultatory finding of either a diastolic murmur or a systolic murmur of grade 4 or 
above by a trained physician assistant was considered as positive for presence of a valvular 
heart disease (VHD).  A supine 12-lead ECG at rest was obtained using the MAC PC10 
personal cardiogram (Marquette Electronics, Milwaukee, Wisconsin). Electrocardiographic 
data processing, monitoring, and quality control have been described elsewhere(Vitelli, 
Crow et al. 1998). The presence of left ventricular hypertrophy was defined as a Cornell 
voltage >28 mm in men or >22 mm in women when using a 12 lead resting ECG.  A QRS 
duration of >120 ms on a 12 lead resting ECG was used to define prolonged QRS interval.  
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Using stored samples from visit 4 (1996-98), Cystatin C and high-sensitive C reactive 
protein (hs-CRP) were estimated in 2008. The Cystatin C assay employed particle-
enhanced immunonephelometry (N Latex Cystatin C, Dade Behring, Inc., Deerfield, IL) with 
a BNII nephelometer (Dade Behring, Inc., Deerfield, IL) was used (Erlandsen, Randers et al. 
1999). Measurement reliability for blinded quality control replicates of cystatin C was 0.94 
after removing 10 replicate outliers pairs(Folsom, Lutsey et al.). CRP was measured using 
the immunoturbidimetric assay using the Siemens (Dade Behring) BNII analyzer (Dade 
Behring, Deerfield, Il, USA), and reliability coefficient for blind replicates was 0.99(Folsom, 
Lutsey et al. 2009).   
All except two variables i.e., valvular heart disease and serum albumin, were 
available from the visit 4 examination. When using visit 4 as the index visit the baseline 
values of valvular heart disease and serum albumin were carried forward. 
 
Heart Failure 
Incident HF was defined as the first HF hospitalization or presence of HF code on 
death certificate since baseline visit. These events were identified from hospital discharge 
records and death certificates that showed a HF code in any position. International 
Classification of Diseases Code, Ninth Revision (ICD-9) code ‘428.x’, and deaths with ICD-
9/10 codes of either 428.x or I50 were considered as HF.  Follow up for the current analysis 
ended on December 31, 2005.  
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Statistical Methods  
Means (standard deviations) and proportions of characteristics at baseline were 
estimated by incident HF status. Performance measures such as Area Under the ROC 
Curve (AUC) and net reclassification improvement (NRI) were estimated for discrimination, 
and Gronnesby-Borgan (GB) statistics(Gronnesby and Borgan 1996) for model fit. By 
considering censoring in the context of long term risk prediction the AUC can be defined as 
the probability that a person with disease onset by time T0 has a higher risk score than a 
person with no event by time T0, )0)(&1)(|( ==> tDtDZZP jiji  where D(t) is an indicator 
variable for event or no event by time t, and Z denotes risk score. In addition to AUC, the 
NRI for cut-offs (<5%, 5 to <10%, 10 to <20%, and 20% or more) was calculated (Pencina, 
D' Agostino RB et al. 2008; Pepe, Feng et al. 2008) since NRI is more meaningful for clinical 
decision making than the AUC (Pencina, D' Agostino RB et al. 2008). The NRI statistics 
cross tabulate the number of individuals classified into various risk levels (such as low, 
medium, and high) by two models. The movement of individuals between categories could 
be upward, downward, or no reclassification. Based on an individual’s actual outcome, the 
full model may reclassify him/her appropriately (upward movement given an event and 
downward in the absence of an event), or inappropriately. The GB statistics were used to 
measure the goodness of fit of the risk score by deciles of the function. By computing the 
martingale residuals for each decile the GB statistic tests the hypothesis that the expected 
value of the sum of these residuals is equal to zero (May and Hosmer 1998).   
 
Cox proportional hazard models were used to estimate age independent hazard 
ratios for presence vs. absence (categorical variables), and per SD increment (for 
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continuous variables). AUC and GB statistics were estimated for functions with age and 
each independent variable.  
 
To test the external validity of the extant risk functions in the ARIC study first we 
estimated the risk score for each participant using published regression coefficients from the 
extant functions  multiplying them by the respective variables. A Cox regression model was 
the fit with the risk function as the sole independent variable and performance statistics 
were estimated. We did this for both 5 and 10 years of follow up. The AUC estimates were 
stable after 5 years.  
 
To estimate the ARIC risk function multivariable Cox regression with backward 
elimination (using a stay p value of 0.1) was fit to the full ARIC cohort. All variables in Table 
11 except for race and gender were retained.  The ARIC HF risk score was compared with 
both Framingham risk score and Health ABC risk score. For the estimation of performance 
statistics for the Framingham and the Health ABC risk scores we used both published 
regression coefficients(Kannel, D'Agostino et al. 1999; Butler, Kalogeropoulos et al. 2008), 
and regression coefficients derived within ARIC cohort using the variables in the  respective 
risk scores.  
 
To obtain stable estimates for AUC corrected for optimism (due to fitting the risk 
score in the same sample from which it was derived), 1000 bootstrap samples were 
processed since bootstrapping provides stable estimates with lower bias compared to split-
sample and cross-validation (Steyerberg, Harrell et al. 2001), permits the use of the entire 
dataset and allows for the estimation of the error rates/the reduction of bias of effect 
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estimates. The average optimism i.e., (measure bootstrap samples – measure original dataset) was 
subtracted from the original performance measure. 
 
The incremental value of biomarkers was evaluated using ARIC visit 4 as baseline 
and fitting a basic model without biomarkers and a full model that included biomarkers. 
AUC, NRI, and GB statistics were estimated to compare the risk functions. 
 
Results 
Over the course of 15.5 years if follow-up an incident HF event occurred in 1487 of 
the 13,555 participants (11%). When using the 4th cohort examination as baseline, 647/9144 
(6.6%) of the cohort members developed HF through 2005, for an average follow up of 7.9 
years.  
 
Table 11 describes the characteristics at baseline by incident HF status, The age 
adjusted hazard ratio (HR) and corresponding 95% confidence interval (95% CI) for the 
presence of the characteristic or per unit increase in the standard deviation, the AUC and 
the GB statistics are also shown in Table 11. Briefly, diabetes/blood glucose, 
hypertension/systolic blood pressure, BMI, and pack years of smoking contributed  most to 
the AUC as increments to the AUC derived from a model that includes only age.  
When using backward elimination in the full cohort with p<=0.1 to retain a variable all 
variables include in Table 11 were retained, except for gender and race. Thus, the ARIC HF 
risk score included the following variables: age, race, gender, prevalent CHD, valvular heart 
disease, left ventricular hypertrophy, hypertension, diabetes, QRS duration >120 ms, 
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smoking status, pack-years of smoking, COPD,  systolic blood pressure, heart rate, HDL 
and LDL cholesterol, body mass index, fasting glucose, serum creatinine and albumin..  
Table 12a-b presents these variables and their corresponding beta coefficients and hazard 
ratios overall, and by race and gender. Some variability in the magnitude and direction of 
associations may be seen by race and gender but there is limited statistical power to 
characterize these associations in subsets of the cohort. Table 13 presents the AUC and 
model fit statistics for ARIC, Framingham and the Health ABC risk functions. For the latter, 
the AUC were estimated using the published beta estimates from the respective cohorts  
and also estimated in the ARIC cohort using the variables included in the Framingham and 
the Health ABC HF risk scores, respectively. The AUC from the ARIC HF risk function  was 
higher at 0.8101, 95% CI = 0.8065, 0.8125 (optimism corrected = 0.808) than the AUC 
estimated in the ARIC cohort using variables from the Framingham HF risk score (0.7618), 
and with the variables in the Health ABC risk score (0.7835). The  AUC using published 
coefficients from the Framingham and the Health ABC HF risk scores were 0.6139, and 
0.7848, respectively. Addition of the biomarkers cystatin C and hs-CRP to the ARIC HF risk 
score improved the AUC by 0.004, NRI = 5.2% (Table 14 and 15a).  
 
Reclassification using the ARIC HF risk score improved overall classification for 
23.5% individuals compared to Framingham HF risk score, and 12.8%  compared to Health 
AB HF risk score (Tables 15b – 15c).  The overall goodness of fit by decile of risk score 
was good for the three risk functions, although  the sensitivity of the GB test to the large 
number of events lead to a p<0.001 for all test risk scores. 
Figure 7 shows the observed vs. predicted event rates/frequencies by deciles of risk score 
using published beta estimates from the Framingham and Health ABC studies. The 
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discrimination as well as fit to the ARIC cohort using Framingham risk score appear to be 
poor, whereas the Health ABC estimates fit well to the ARIC cohort. Figure 8 displays the 
predicted and observed events in the ARIC cohort from the  ARIC risk function, by decile of 
risk prediction score. In Figure 9 the ten-year predicted risk of HF by deciles of three risk 
functions are shown, as derived in the ARIC cohort using variables from  Framingham and 
the Health ABC HF risk scores. 
 
Discussion 
We derived a function to estimate the 10-year risk of incident HF in a population 
sample of men and women aged 45-64 years, using variables easily available to the primary 
care physician. Compared to the extant HF risk scores this ARIC HF risk function performed 
better in terms of discrimination, using both traditional (Area Under the Curve) and novel 
(Net Reclassification Improvement) statistics when using the variables or published 
coefficients from the existing risk scores. The NRI was 23.5% using Framingham variables 
fit in the ARIC cohort; the corresponding NRI when compared to the Health ABC variables 
was 12.8%.  Overall, the goodness of fit across decile of risk was satisfactory.  
 
The Framingham HF risk score did not perform well in this sample of middle aged 
blacks and whites drawn from four US communities, even when applied to whites with either 
hypertension or valvular heart disease, or left ventricular hypertrophy.  The discrimination 
achieved using the Health ABC risk score, based on a cohort of healthy older adults, was 
good.  The addition of few variables used in the ARIC HF risk score did improve the AUC 
and net reclassification obtained with the Health ABC HF function.  
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Heart Failure is the culmination of diverse and complex pathological processes 
resulting in insufficiency by the heart to circulate blood at normal pressures to meet 
physiologic needs (Braunwald, Zipes et al. 2001). In this respect it is of interest to see a 
discrimination ability for HF, e.g., the  AUC, considerably  higher than what is generally seen 
for  CHD risk prediction, especially among women(D'Agostino, Grundy et al. 2001). Heart 
rate, ECG-defined left ventricular hypertrophy, and the QRS interval are readily available to 
a primary care physician from a 12 lead ECG. Similarly, BMI, smoking status, history of 
COPD, and laboratory parameters such as serum albumin, cholesterol, typically are 
available. The inclusion of the latter  variables in the prediction of HF improves AUC by 
about 5% and leads to NRI of 23.5% relative to the Framingham HF risk score.  
 
Though prognostic risk scores are commonly used in clinical practice for many 
diseases such as breast cancer, coronary heart disease, mortality post organ transplant 
among others, the use of such tools in the prediction of HF may not be widespread. Barriers 
to their use need examination. One can posit that risk scores are accepted and optimally 
useful in clinical practice if they are perceived to be consistent with clinical guidelines that 
frame the evaluation and management of the conditions they focus on.  Convenient access 
to the predictor variables in the risk score, ease of use, parsimony in the number of predictor 
variables and the ability to modify the factors that adversely influence a patient’s risk also 
seem influential for acceptability in clinical practice.  Optimizing a risk score for use in 
clinical practice was not in the scope of the current work.. However, such work is an 
important as a step to draw on the desirable properties of the model developed here.  A risk 
score with these characteristics that can penetrate clinical practice can serve to identify 
patients at intermediate predicted risk levels who may benefit from timely use of diagnostic 
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testing such as echocardiogram, referral to cardiologist, and regularly scheduled visit. 
Similarly, those at high levels of predicted risk would be identified as candidates for 
aggressive management of risk factors to delay development of HF and improve outcomes.  
 
Among the strengths of this study is the derivation of a risk score in a large 
community-based cohort of middle aged white and black men and women, with long term 
follow-up and high retention rates. There are also limitations worth noting.  Although similar 
to that of the Health ABC study and other cardiovascular disease cohorts, the classification 
of HF as the outcome was not validated. A recent validation study based on a large sample 
of hospitalizations discharged with  ICD codes with high suspicion of HF indicates that the 
predictive value positive (PPV) of an ICD code ‘428.x’ for HF classified by a physician 
review panel was 77%, and the sensitivity was 95% (Rosamond, Chang et al. 2009).  The 
corresponding PPV and sensitivity of Framingham Heart Failure criteria were 0.78, and 
0.83, respectively(Rosamond, Chang et al. 2009). Thus, the HF outcome based on hospital 
discharge ICD codes used in our analyses may be considered at least as good as the 
Framingham HF diagnostic criteria. However, it should be noted that our study would miss 
HF cases managed successfully in outpatient settings if they were not hospitalized 
throughout the 15.5 year follow up period.    
 
The performance in, and generalizability to non-white, non-black groups of the ARIC 
HF risk score and equivalent risk functions need to be examined.  There is a remarkable 
lack of information in this regard.  Replication of our study findings in other population based 
cohorts is required, and may result in calibration according to differences in  risk of HF.  
Future studies are also encouraged to consider the addition of biomarkers predictive of HF, 
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to test whether improvements in risk prediction can be achieved while considering the costs 
and benefits of their inclusion.  
 
We conclude that the ARIC HF risk score performs well in predicting 10-year risk of 
hospitalized HF in community settings, with results based on a large cohort of middle aged 
black and white men and women. The performance of this risk score appears to be better 
than that of extant HF risk scores.  These findings need replication, and possibly calibration, 
in other cohorts. Early identification of susceptibility to HF and its efficient monitoring in 
community settings may contribute to proactive risk management and to the reduction in the 
growing burden of decompensated HF.  
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Table 11.  Characteristics at baseline by heart failure during follow up, age adjusted hazard ratios, 
AUC, and GB statistics   
Characteristics HF during follow up* SD Hazard ratio
¶
 AUC
||
 
Gronnesby-Borgan 
test
§
 
 
Yes  
(n=1487) 
No  
(n=12068)  HR  95%CI  
Chi-
square P value 
Age
# 
 (years) 56.6 53.8 5.8 1.69 1.60 1.78 0.638 6.73 0.665 
Male  0.54 0.44  1.43 1.29 1.58 0.653 2.12 0.990 
Black 0.34 0.25  1.78 1.60 1.98 0.660 18.33 0.032 
Prevalent CHD 0.13 0.03  4.23 3.63 4.93 0.669 23.25 0.006 
Valvular heart disease 0.04 0.01  2.72 2.12 3.50 0.645 15.56 0.077 
Left ventricular hypertrophy 0.06 0.01  3.89 3.15 4.80 0.652 23.29 0.006 
Hypertension 0.54 0.3  2.34 2.11 2.60 0.684 19.84 0.019 
Diabetes 0.29 0.08  3.86 3.45 4.32 0.695 50.30 0.000 
QRS duration >120 ms 0.07 0.03  2.32 1.91 2.82 0.648 7.35 0.601 
Current smoking 0.37 0.24  2.14 1.92 2.38 0.672 6.88 0.649 
Former smoking 0.32 0.32  0.95 0.86 1.06 0.643 4.84 0.848 
COPD 0.12 0.08  1.63 1.39 1.90 0.646 13.19 0.154 
Systolic blood pressure 
(mmHg) 130.0 119.8 18.7 1.48 1.42 1.55 
0.689 
25.52 0.002 
Heart rate (beats/minute) 68.9 66.2 10.2 1.31 1.25 1.37 0.668 11.48 0.244 
HDL cholesterol (mg/dl) 47.2 52.7 17.0 0.68 0.64 0.72 0.678 13.01 0.162 
LDL cholesterol (mg/dl) 143.3 136.9 39.1 1.47 1.40 1.53 0.652 12.83 0.170 
Body mass index (kg/(m*m)) 29.6 27.3 5.2 1.47 1.40 1.53 0.687 12.01 0.213 
Fasting glucose (mg/dL) 130.2 104.6 37.4 1.38 1.34 1.41 0.685 93.84 0.000 
Log (serum creatinine in 
mg/dl) 0.1 0.1 0.2 1.26 1.21 1.32 0.665 16.23 0.062 
Serum albumin (mg/dL) 3.8 3.9 0.3 0.72 0.69 0.76 0.674 7.59 0.576 
Pack-years of smoking 24.0 14.6 21.3 1.37 1.32 1.43 0.680 14.93 0.093 
SD = Standard Deviation, AUC = Area Under Curve of a receptor operating function, CHD = Coronary Heart Disease,  COPD = 
Chronic Obstructive Pulmonary disease (self report of a physician diagnosis) 
* 
Expressed as Mean and Standard deviation (SD) or Percentages
 
¶ 
Each row represents a model. For variables other than age, models includes age as a simultaneous independent variable; 
hazard ratio contrasts presence of a categorical characteristics versus its absence; and  per SD unit increase in the 
continuous variable, independent of age.
 
|| 
AUC is calculated over 10 years of follow up 
§
GB test has 9 degree of freedom corresponding to nine indicator variables to represent deciles. 
#
Model has only age as an independent variable
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Table 12a.   Regression coefficients (log of hazard ratio of heart failure ) from multivariable models fit with the variables in 
the basic ARIC heart failure risk score, for all participants and by race and gender ; the ARIC cohort 
Variables All*  White Black 
  Women Men Women Men 
Prevalent CHD 1.170 1.355 1.286 0.563 0.941 
Valvular heart disease 0.660 0.451 0.616 1.051 0.583 
Left ventricular hypertrophy 0.702 1.026 0.831 0.942 0.344 
Hypertension 0.257 0.434 0.166 -0.075 0.534 
Diabetes 0.522 0.553 0.507 0.631 0.622 
QRS duration >120 ms 0.473 0.668 0.449 -0.268 0.687 
Current smoking 0.791 1.051 0.661 0.759 0.380 
Former smoking 0.149 -0.025 0.081 0.268 0.031 
COPD 0.345 0.609 0.227 0.170 -0.124 
Age (years) 0.068 0.081 0.075 0.059 0.045 
Systolic blood pressure (mm Hg) 0.011 0.009 0.013 0.011 0.010 
Heart rate (beats/minute) 0.018 0.018 0.021 0.015 0.021 
HDL cholesterol (mg/dl) -0.006 -0.003 -0.004 -0.003 -0.017 
LDL cholesterol (mg/dl) 0.002 0.000 0.002 0.001 0.002 
Body mass index (kg/(m*m)) 0.045 0.058 0.065 0.029 0.022 
Fasting glucose (mg/dL) 0.004 0.004 0.003 0.005 0.001 
Log (serum creatinine in mg/dl) 1.004 0.630 0.434 1.240 0.447 
Serum albumin (mg/dL) -0.816 -0.409 -1.031 -0.765 -1.149 
Pack-years of smoking 0.007 0.007 0.007 0.007 0.008 
CHD = Coronary Heart Disease, COPD = Chronic obstructive Pulmonary Disease,  
*In the full model with above variables and also race and gender fitted to the ARIC cohort, race and gender are dropped when using 
backward elimination and a p-stay = 0.1. Also, all variables had a p<0.001 except for former smoker (0.047), LDL (0.016), and HDL 
(0.001) 
For white female the following variables were dropped at 0.1 level: Former smoking, HDL-C, LDL-C, and VHD  
For black female the following variables were dropped at 0.1 level: Former smoking, HDL-C, Prolonged QRS interval, and Hypertension.  
For white male the following variables were dropped at 0.1 level Former smoking, HDL-C, creatinine, and COPD 
For black male the following variables were dropped at 0.1 level: Former smoking, LDL-C,  glucose, and BMI 
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Table 12b. Heart failure  hazard ratio estimates from multivariable models fit with the variables 
in the basic ARIC heart failure risk score, for all participants and by race and gender ; the ARIC 
cohort 
Variables All*  White Black 
  Women Men Women Men 
Prevalent CHD 3.22 3.88 3.62 1.76 2.56 
Valvular heart disease 1.93 1.57 1.85 2.86 1.79 
Left ventricular hypertrophy 2.02 2.79 2.30 2.57 1.41 
Hypertension 1.29 1.54 1.18 0.93 1.71 
Diabetes 1.69 1.74 1.66 1.88 1.86 
QRS duration >120 ms 1.61 1.95 1.57 0.77 1.99 
Current smoking 2.21 2.86 1.94 2.14 1.46 
Former smoking 1.16 0.98 1.09 1.31 1.03 
COPD 1.41 1.84 1.26 1.19 0.88 
Age  1.48 1.59 1.54 1.40 1.29 
Systolic blood pressure 1.23 1.19 1.27 1.22 1.21 
Heart rate  1.21 1.20 1.23 1.17 1.24 
HDL cholesterol 0.90 0.96 0.93 0.94 0.76 
LDL cholesterol  1.06 1.02 1.08 1.05 1.08 
Body mass index  1.27 1.35 1.41 1.16 1.12 
Fasting glucose  1.17 1.17 1.12 1.22 1.04 
Log (serum creatinine) 1.21 1.12 1.08 1.26 1.09 
Serum albumin  0.81 0.90 0.76 0.82 0.74 
Pack-years of smoking 1.17 1.17 1.17 1.15 1.18 
The hazard ratio for continuous variable are given per standard deviation (from the overall 
cohort) 
 
  
 
 
Table 13. Discrimination and Goodness of Fit statistics for  models optimized to predict the 10-year risk of heart failure 
  Area Under Curve Gronnesby-Borgan chi-square (p value) 
Samp
le  Framingham Health-ABC 
ARIC 
basic Framingham Health-ABC 
ARIC-
basic 
  
Publishe
d 
 beta  
Derived  
beta 
Publishe
d  
beta  
Derived  
beta  
Publishe
d  
beta  
Derived  
beta 
Publishe
d  
beta  
Derived  
beta  
All  0.614 0.762 0.785 0.783 0.812 <0.001 <0.001 <0.001 <0.001 <0.001 
 Male 0.727 0.764 0.772 0.773 0.801 <0.001 <0.001 <0.001 <0.001 <0.001 
 
Femal
e 0.700 0.766 0.790 0.790 0.820 <0.001 <0.001 <0.001 <0.001 <0.001 
 
 
 
 
 
 
Table 14. Discrimination and goodness of fit statistics comparing the basic ARIC heart failure risk 
score model with a full model including  biomarkers  
 ARIC basic  ARIC biomarkers 
AUC 0.790 0.794 
GB test chi-square 28.61 27.15 
GB p value 0.0008 0.001 
AUC = Area Under Curve; GB = Gronnesby-Borgan statistics 
Additional biomarkers include cystatin-C and high sensitive C reactive protein.  
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Table 15c.   Net improvement on reclassification of  individual risk of heart failure using the variables in the basic ARIC risk score and those in the ARIC risk score with biomarkers. 
Table 15a. ARIC HF Risk score model with biomarkers    
ARIC basic 
model <5% 5 to <10% 10 to <20% 20% or more Overall 
 n  
row 
% Risk n  
row 
% Risk n  
row 
% Risk n  
row 
% Risk n  % Risk 
<5% 5031 96.05 0.022 205 3.91 0.068 1 0.02 0 1 0.02 0 5238 53.5 0.024 
5 to <10% 253 10.91 0.013 1911 82.41 0.063 148 6.38 0.181 7 0.3 0.143 2319 23.69 0.066 
10 to <20% 0 0 . 176 12.95 0.131 1096 80.65 0.153 87 6.4 0.446 1359 13.88 0.163 
20% or more 0 0 . 0 0 . 79 9.03 0.188 796 91 0.369 875 8.94 0.351 
Overall 5284 53.97 0.022 2292 23.41 0.069 1324 13.52 0.157 891 9.1 0.369 9791 100 0.08 
                
NRI 0.05248               
ARIC = Atherosclerosis Risk In Communities Study, NRI = Net Reclassification Improvement ; basic refers to model without biomarkers 
but only variables routinely available to primary care physicians.  
Additional biomarkers include cystatin C and C-reactive protein 
 
 
 
 
 
Table 15b.  Net improvement on reclassification of  individual risk of heart failure using the variables in the basic ARIC risk score and 
those in the Framingham heart failure risk score 
 ARIC- basic HF Risk Score model   
Framingham 
Risk Model <5% 5 to <10% 10 to <20% 20% or more Overall Sample 
 N  
row 
% Risk n  
row 
% Risk n  
Row 
% Risk n  
row 
% Risk n  % Risk 
<5% 8742 90.23 0.014 830 8.57 0.079 106 1.09 0.119 11 0.11 0.273 9689 71.48 0.021 
5 to <10% 1046 45.05 0.031 815 35.1 0.075 378 16.28 0.178 83 3.57 0.348 2322 17.13 0.08 
10 to <20% 62 5.81 0.05 371 34.77 0.092 427 40.02 0.171 207 19.4 0.344 1067 7.87 0.166 
20% or more 2 0.42 0 23 4.82 0 127 26.62 0.173 325 68.1 0.382 477 3.52 0.303 
Overall 9852 72.68 0.016 2039 15.04 0.079 1038 7.66 0.168 626 4.62 0.363 13555 100 0.051 
                
NRI 0.235               
 
Framingham = Framingham Heart Failure Risk Score model; ARIC = Atherosclerosis Risk In Communities Study, NRI = Net 
Reclassification Improvement ; basic refers to model without biomarkers but only variables routinely available to primary care 
physicians.  
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Table 15c.  Net improvement on reclassification of  individual risk of heart failure using the variables in the basic ARIC risk score and 
those in the Heath-ABC heart failure risk score 
 ARIC-basic HF Risk Score model    
Health ABC 
Risk Model <5% 5 to <10% 10 to <20% 20% or more Overall Sample 
 n  
row 
% Risk n  
row 
% Risk n  
row 
% Risk n  
row 
% Risk n  % Risk 
<5% 9145 93.78 0.014 563 5.77 0.064 42 0.43 0.074 2 0.02 . 9752 71.94 0.017 
5 to <10% 698 30.24 0.042 1215 52.64 0.083 368 15.94 0.171 27 1.17 0.224 2308 17.03 0.087 
10 to <20% 9 0.92 0 259 26.35 0.091 523 53.2 0.157 192 19.5 0.325 983 7.25 0.171 
20% or more 0 0 . 2 0.39 0.5 105 20.51 0.257 405 79.1 0.395 512 3.78 0.367 
Overall 9852 72.68 0.016 2039 15.04 0.079 1038 7.66 0.168 626 4.62 0.363 13555 100 0.051 
                
NRI 0.128               
Health ABC = Health ABC Study Heart Failure Risk Score model; ARIC = Atherosclerosis Risk In Communities Study, NRI = Net 
Reclassification Improvement ; basic refers to model without biomarkers but only variables routinely available to primary care 
physicians.  
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Figure 7. Panel a. Four-year observed and expected HF events by decile of 
linear risk, estimated by applying published Framingham beta estimates to the 
ARIC cohort (year-year), Panel b. Fifteen-year observed and expected HF events 
by decile of linear risk, estimated by applying published Health-ABC beta 
estimates to the ARIC cohort , (1987-2005). 
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Figure 7. Panel a. Four-year observed and expected HF events by decile of 
linear risk, estimated by applying published Framingham beta estimates to the 
ARIC cohort (year-year), Panel b. Fifteen-year observed and expected HF 
events by decile of linear risk, estimated by applying published Health-ABC beta 
estimates to the ARIC cohort , (1987-2005). 
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Figure 8. Number of observed versus predicted heart failure events during study 
follow up by decile of the ARIC heart failure risk score. Each decile includes 
approximately 1355 individuals at study baseline.  
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Figure 9. Ten year probability of heart failure by the decile of risk of the 
Framingham, Health ABC, and ARIC heart failure risk functions as fit on the full 
ARIC cohort.  
 
  
Chapter V 
V. CONCLUSIONS  
A. Recapitulation  
This project examined the association of obstructive airway disease (lung function) 
and incident heart failure in a large population based cohort. Also, it evaluated the external 
validity of two extant risk scores to predict heart failure, developed a novel risk score to 
predict ten years risk of heart failure in community settings,  and tested the incremental 
value of two biomarkers to risk prediction.  
 
B. Discussion of results 
We observed a strong inverse association between baseline lung function with 
incident HF, and a monotonic, direct association between airflow obstruction and incident 
HF. These associations were seen across groups defined by race, gender, and smoking 
status. Notably, the relationship was seen in never-smokers and after adjustment for 
smoking status and cigarette-years of smoking, indicating that our results are not primarily 
confounded by smoking.  
 
These results in a population-based cohort are consistent with clinical observations, 
but also with two prior reports from population based cohorts. The present study extends 
these results by the length and completeness of its follow-up, a replication in African 
Americans, and by examination of markers of chronic inflammation a potential mechanism. 
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Also, consistent association of interviewer-ascertained chronic bronchitis, self 
reported COPD and emphysema, and airway obstruction (FEV1/FVC<70%) with incident 
HF, but not with asthma was found. The weak but statistically significant association of 
asthma with incident HF among women could be explained by misdiagnosis of COPD for 
asthma in primary care, reportedly more common in women than in men. Our results are 
similar to those of a large retrospective case control study based on claims data. These 
associations were seen with moderate/severe COPD (defined with spirometry) and not 
with mild disease. Consistent association by race, gender, smoking group; replication of 
study findings in at least one other cohort; and several potential mechanisms explaining 
this association suggest that these results are robust.  
 
While the Framingham HF risk prediction model did not perform well when applied 
to the ARIC cohort, the Health ABC risk function performed well. The ARIC HF risk score 
includes additional variable easily available to primary care physicians and had a better 
performance as quantified by an appropriate reclassification of individuals’ risk compared 
to either Framingham or Health ABC risk score. Further, through it we extended the risk 
score estimations to ten years. Two biomarkers predictive of HF in the ARIC cohort added 
only slightly to improvements in risk prediction. The results from this research need to be 
replicated in independent cohorts and additional biomarkers should be tested for their 
ability to further improve risk prediction.  
 
 In conclusion, in this large population based closed cohort study with long term 
follow up, we observed that low FEV1, low FVC, self reported COPD, and airway 
obstruction are associated with incident HF. Improved survival following CHD and an 
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increase in other risk factors have increased the pool of patients with HF. Given the 
profound implications of HF at the population level in terms of loss of quality of life, 
mortality and societal costs, the prevention of COPD through programs on smoking 
cessation, ambient air quality and occupational exposures may contribute to reduce the 
burden of HF.  
 
The ARIC HF risk score appears to be a better tool for risk stratification of middle-
aged individuals in community settings than the extant risk scores. If replicated in 
independent samples, this score may help in early identification, referral, and management 
of patients at high risk of future heart failure. This has strong potential to improve  the 
primary prevention of decompensated HF.  
 
C. Degree to which doctoral goals have been met 
The Academic Policies Manual published by the Department of Epidemiology 
recommends that doctoral research show accomplishments in four areas, as follows: a). 
High degree of originality, b). Depth, c). Scholarship, and d). Writing skills. The 
manuscripts based on this doctoral research were prepared with input from the doctoral 
committee members, and other co-authors with expertise both in the substantive areas 
and in methodology.  
 
We submit that this work meets the expectations for doctoral research to a 
significant extent. a) Originality: To our knowledge this study is the first to examine the 
prospective association between airway obstructive disease measured in several, 
complementary ways and incident HF. Thus, the study adds to the limited literature on 
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spirometry indexes and incident HF and examines the potential role of 
inflammatory/coagulation markers in this association. Further, this is the first community 
based study to develop a risk score to predict ten year-risk of heart failure, and it uses 
recently proposed methods to test the performance of risk prediction models. This is also 
the first study to examine the incremental value of C reactive protein to HF risk prediction. 
b). Depth: this project uses longitudinal data analysis from two broad perspectives i.e., 
exposure-disease association and risk prediction. Both traditional and novel methods for 
risk prediction are used for this purpose and substantive knowledge about the exposure, 
the outcome and its classification, and on optimism in the estimation of risk function 
performance were used for additional analysis. c). Scholarship: this work applied rigorous 
research methods and has a potential to aid in prevention and management of heart 
failure. The first manuscript was nominated a finalist for a prestigious award at the 2009 
AHA Epidemiology conference. d). Writing skills: Beyond the present work, I have been 
able to contribute to the writing of several manuscripts during my doctoral training, several 
of which have been published in peer review journals.  
 
D. Strengths and Limitations  
The strengths of the study on airflow obstruction and HF include their prospective 
and population-based nature, their internal consistency including among non-smokers, the 
sizeable magnitude of hazard ratio estimates even after multivariable adjustment, and the 
imperviousness of the results to various sensitivity analyses. The strength of risk prediction 
of HF study includes development of a risk score in a large sample of community based 
black and white men and women to predict long term risk, well characterized predictors at 
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baseline, replication of performance using another baseline 12 years apart, and testing 
incremental value of two biomarkers to risk prediction.  
 
Among the limitations, the most important is the lack of validation and detailed 
characterization of the heart failure events. Further, the respiratory symptoms and 
diagnoses were self reported and not validated.  Perhaps less worrisome, smoking status 
was self reported and not validated with biomarkers, thus some residual confounding due 
to smoking could not be ruled out, and neither post bronchodilator lung function or total 
lung volume were measured. Lastly, although adjustment for BMI did not influence the 
estimates, residual confounding due to sleep apnea could not be ruled out.  
 
E. Future Directions 
Replication of study results in independent cohorts for both studies is required. 
Studies that have the capacity for  better characterized heart failure outcome would be 
desirable for purposes of replication and could provide important information about 
potential pathways linking COPD with HF. Further, it remains to be examined whether 
additional biomarkers such as N-terminal Brain Natriuretic Peptide or hs-troponin can 
improve risk prediction of HF, either alone or in combination.  
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Table 16. Quartile boundaries of FEV1 and FVC by race and gender  
Race Gender n 
 
Lower 
Quartile Median 
Upper 
Quartile 
Female 5431 FEV(1) 
(liters) 
FVC (liters) 
2.21 
2.98 
2.54 
3.36 
2.84 
3.74 
Whites 
Male 4862 FEV(1) 
(liters) 
FVC (liters) 
2.98 
4.17 
3.47 
4.70 
3.91 
5.24 
Female 2063 FEV(1) 
(liters) 
FVC (liters) 
1.93 
2.52 
2.24 
2.87 
2.53 
3.23 
Blacks 
Male 1304 FEV(1) 
(liters) 
FVC (liters) 
2.62 
3.53 
3.02 
3.98 
3.41 
4.43 
 
 
  
 
 
 
Table 17. GOLD classification and risk of incident heart failure: The ARIC study  
GOLD staging # % cohort 
Row % 
incident HF 
Rate Ratio 
(95%CI)  
Model 1 
Rate Ratio (95%CI)  
Model 2 
No lung disease 9760 71.5 7.9 1 
1 
At risk of COPD 301 2.2 10.6 1.45(1.01, 2.06) 1.32(0.92, 1.88) 
Restrictive 609 4.5 23.2 3.07 (2.56, 3.67) 1.82 (1.51, 2.19) 
Mild COPD 1492 10.9 8.9 0.92 (0.76, 1.11) 0.98 (0.81, 1.20) 
Moderate COPD 1281 9.4 18.2 2.03 (1.74, 2.35) 1.60 (1.37, 1.87) 
Moderate/severe COPD 217 1.6 29.6 3.95 (3.06, 5.10) 3.40 (2.60, 4.44) 
Model 1 adjusts for age.  
Model 2 adjusts for age, prevalent CHD, traditional CHD risk factors, and BMI.  
Rate ratios generated using Proc Genmod routine and assuming Poisson distribution in SAS.  
In model 1, the estimates are much larger in female than males. For e.g. Restrictive is (3.59 vs. 2.70); severe COPD is (5.00 vs. 
3.98). Similarly, the estimates were much larger for whites than blacks, for e.g. for restrictive (3.97 vs. 1.74); and for Severe COPD 
(4.35 vs. 3.41).  
In model 2, the estimates were much larger for females than males, for e.g. for restrictive (1.95 vs. 1.74); and for Severe COPD 
(4.37 vs. 2.84). Similarly, the estimates were much larger for whites than blacks, for e.g. for restrictive (2.25 vs. 1.25); but not for 
Severe COPD (3.48 vs. 3.58).  
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Table 18. Obstructive, and Restrictive, lung disease and incident heart failure  
GOLD staging # % cohort 
Row % incident 
HF 
Rate Ratio (95%CI)  
Model 1 
Rate Ratio 
(95%CI)  
Model 2 
No lung disease OR At 
risk of COPD OR Mild 
COPD 
11553 84.6 8.1 1 
1 
Moderate/severe COPD 1498 11.0 19.9 2.32(2.04, 2.65) 1.84 (1.60, 2.12) 
Restrictive 609 4.5 23.2 3.10 (2.60, 3.70) 1.67 (1.39, 2.01) 
Model 1 adjusts for age.  
Model 2 adjusts for age, prevalent CHD, traditional CHD risk factors, and BMI.  
 
1
0
9
 
  110 
C. Supplemental Results, Manuscript 2 
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Figure 10. Number of observed versus predicted HF events during study follow 
up by decile of Framingham HF risk score. In each decile there were 
approximately 1355 individuals at baseline.  
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Figure 11. Number of observed versus predicted HF events during study follow 
up by decile of Health ABC HF risk score. In each decile there were 
approximately 1355 individuals at baseline.  
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Figure 12. Ten years probability of heart failure by the deciles of risk functions i.e. 
ARIC HF risk score, and ARIC HF risk score with addition of cystatin C and C 
reactive protein. Variables from respective risk score were fitted in multivariable 
models using the complete ARIC cohort. 
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